

EYE, RETINA, AND VISUAL SYSTEM OF THE MOUSE

Edited by Leo M. Chalupa and Robert W. Williams

THE MIT PRESS
CAMBRIDGE, MASSACHUSETTS
LONDON, ENGLAND

© 2008 Massachusetts Institute of Technology

All rights reserved. No part of this book may be reproduced in any form by any electronic or mechanical means (including photocopying, recording, or information storage and retrieval) without permission in writing from the publisher.

For information about special quantity discounts, please email special_sales@mitpress.mit.edu

This book was set in Baskerville by SNP Best-set Typesetter Ltd., Hong Kong.

Printed and bound in the United States of America.

Library of Congress Cataloging-in-Publication Data

Eye, retina, and visual system of the mouse / Leo M. Chalupa and Robert W. Williams, editors.

p. cm.

Includes bibliographical references and index.

ISBN 978-0-262-03381-7 (hardcover : alk. paper)

1. Mice—Sense organs. 2. Eye. 3. Visual pathways.

I. Chalupa, Leo M. II. Williams, Robert W., 1952–

QL737.R6E94 2008

573.8'819353—dc22

2007047445

10 9 8 7 6 5 4 3 2 1

INDEX

Note: Page numbers followed by *f* indicate figures; page numbers followed by *t* indicate tables.

A

- A and A/J strain
auditory evoked brainstem response in, 22
conditioned taste aversion in, 29
hearing and visual abilities in, 15t, 16
mutation and effect in, 62t
pattern discrimination in, 18
taste ability in, 24
visual acuity of, 20
- ABCA4* mutations, 723
- Abca4/Abcr* null mutant mice, Stargardt
macular degeneration in, 540–542,
541f
- Ablation, targeted, to assess role of
photoreceptors, 595–596
- ab-LIM, directed growth of retinal ganglion
cell axons toward optic disc and, 384
- AC Master, 78, 78f
- Acanthamoeba* infections, 508–509
- α A/CAT transgenic mice, 273
- Achromatopsia, gene replacement therapy
for, 612–613
- Acoustic startle test, 22
- Adenoassociated virus (AAV) gene therapy,
605–614
antiangiogenic, 607
for choroidal neovascularization, 610
future directions for, 613–614
gene replacement strategies and, 610–613
for functional defects in retina, 611–613
for structural defects in retinal disease,
610–611
for retinal neovascularization, 607,
609–610
vectors for, 605–607, 606t, 608t–609t
- Advanced glycation end products (AGEs),
diabetic retinopathy and, 552
- African pygmy mice, 3, 5, 8
- Age-related eye diseases, 581–588
cataracts as, in human and mouse eyes,
588
in mice, search for, 581–582, 583t–584t
mouse models for, 581
- Age-related macular degeneration (AMD)
gene therapy for, 607
in human and mouse eyes, 582, 584–588
- Age-related retinal degeneration (ARRD), in
human and mouse eyes, 582,
584–588, 585f–587f, 585t
- Akita mice, diabetes in, 549
retinal neurodegeneration induced by, 551
- AKR/J strain
auditory evoked brainstem response in,
22
hearing and visual abilities in, 15t, 16
pattern discrimination in, 18
taste ability in, 23
visual acuity of, 20
- Albinism, retinal ganglion cell projections
and, 397
- Albino mice, 61
pattern discrimination in, 18
visual acuity of, 20
- Aldose reductase, diabetic retinopathy and,
552
- Alleles. *See also specific alleles*
defining disease progression, clinical
outcome, or important domains,
650
defining response to treatment, 651
defining responses to environmental
influences, 650–651
phenotypic variation due to, 649–651
- Allen Brain Atlas, search of, for RALDH3
colocalized genes, 370–371, 372f
- All-*trans*-retinol dehydrogenase, in visual
cycle, 722–723
- Amacrine cells
cholinergic (starburst)
mosaic architecture of, 150–151, 151f
study approaches for, 598
dopaminergic
genetic labeling of, 597–598
mosaic architecture of, 151–153
gap junctions of, 167
glucagon, in mouse versus chicken eye,
82–83
transgenic mice for study of, 597–598
V-amacrine, 597
- AMPA, excitatory lateral geniculate nucleus
responses and, 420, 422
- AMPA receptors (AMPArs), 223–225
long-term depression and, 470
in reticulogeniculate synapses, 431, 439
- Anaphase-promoting complex (APC), retinal
ganglion cell axon growth ability and,
408
- Anesthesia dolorosa, model of, 25
- Angioblasts, 285
- Angiogenesis, 285–286, 639–641
hyaloid vessel regression versus, in norrin
deficient mice, 532, 533f
sprouting, failure in, in norrin deficient
mice, 531–532
VEGF-A in, 640–641
- Angiopoietin, diabetic retinopathy and,
552–553
- Angiopoietin/Tek system, retinal
vascularization and, 292
- Angiostatin, anti-angiogenic properties of,
610
- Angular vestibulo-ocular reflex (aVOR),
88–91, 89f, 90f
- gain and response axis of, adaptation of,
96–98, 97t
- Anophthalmic mice, 269, 271
- Anterior chamber, cell types in, 644–645
- Anterior chamber–associated immune
deviation (ACAID), 521–522
pigmentary glaucoma and, 483
- Antiangiogenic gene therapy, 607
- Antibodies, against neurofilament H, as
retinal ganglion cell marker, 193
- Antigen-presenting cells (APCs),
experimental autoimmune uveitis
and, 519
- Anxiety-related behavior tasks, 29
- API, in cornea and lens development, 703
- AP2, in cornea and lens development, 703
- AP2 α* , lens development and, 277
- AP2 α -Cre* mice, 275
- Apo-cellular RBP (CRALBP), 724
- Apoptosis. *See* Cell death
- Aquaporin, cataracts and, 495
- Aqueous humor
inflow of, 129, 129f
outflow of, 129–131
uveoscleral, 132–133
- Astrocyte(s)
in optic nerve, 201–202, 202f
retinal vascularization and, 287
- Astrocyte progenitor cells (APCs), 390,
390f
- Atoh7, retinal ganglion cell development
and, 194
- ATP-binding cassette A4, in visual cycle,
723
- Atropine, myopia development and, 83
- Auditory evoked brainstem response (ABR),
20, 22
- Autism spectrum disorders, visual cortical
functions in, 245
- Autoimmune uveitis. *See* Experimental
autoimmune uveitis (EAU)
- Automated visual responses, measures of,
111–115, 114f, 115f
- Avoidance conditioning, active and passive,
27–28
- a-waves, cone, 138
- Axial length, changes in, measurement,
77–79, 78f
- Axons, of retinal ganglion cells. *See* Retinal
ganglion cells (RGCs)

B

- Bacterial artificial chromosome (BAC)
transgenesis, 594, 594f
- Bacterial infections, 506–508
- Bagg, Halsey J., 13

- BALB strains, 62t
- BALB/c
- anxiety-related behavior tasks and, 29
 - auditory evoked brainstem response in, 22
 - conditioned odor preference in, 28
 - learning and memory in, 27
 - pain sensitivity in, 25
 - photoreceptor response damage by light and, 575, 577
- BALB/cByJ
- hearing and visual abilities in, 15t, 16
 - pattern discrimination in, 18
 - visual acuity of, 20
- BALB/cJ
- conditioned taste aversion in, 29
 - hearing and visual abilities in, 15t, 16
 - pain sensitivity in, 25
 - pattern discrimination in, 18
 - visual acuity of, 20
- Barnes maze, 27
- Basic fibroblast growth factor (bFGF), retinal ganglion cell axon growth and, 401
- Batten disease, 612
- Bcl-2
- Bcl-2*-overexpressing retina, 152
 - cell death and, 337f, 337–338
 - retinal neovascularization and, 293
- Beaded filaments, 499
- Behavior, environmental enrichment and, 450
- Behavioral studies of mouse vision, 107–116
- applied measurement of, 115–116, 116f
 - idiosyncrasies associated with whole animal behavior and, 108–109
 - measures of, 109–115
 - of automated visual responses, 111–115, 114f, 115f
 - of visual perception in reinforcement-based tasks, 109–111, 111f–113f
 - rationale for, 107–108
- Behavioral tasks, for sensory function
- measurement, 15t, 15–16
 - future directions for use of, 30
 - of hearing, 20, 22
 - learning and measurement tasks and, 25–29
 - of olfaction, 22–23
 - of pain sensitivity, 24–25
 - of tactile and vibrissae sensitivity, 24
 - of taste, 23–24
 - of vision, 16–20
- BEN, directed growth of retinal ganglion cell axons toward optic disc and, 382–383
- Bfsp1*, cataracts and, 499
- Bfsp2*, cataracts and, 499
- bHLH transcription factors, retinal development and, 303
- BH3-only protein, cell death and, 338
- Binocularity, in primary visual cortex, 49–51, 50f
- transcallosal cells and, 50–51
- Bipolar cells
- Clomeleon in, 597
 - depolarizing, 136
 - synaptic transmission in outer retina and, 176f, 176–179, 177t
 - gap junctions of, 167
 - hyperpolarizing, 136
 - synaptic transmission in outer retina and, 176f, 176–179, 177t
 - ON and OFF pathway segregation and, 353–354, 357
 - in *Rb*-deficient retinas, 315
 - role of gap junctions in, transgenic mice to study, 596–597
 - synaptic output of, control by GABA_CR-mediated inhibition, 182–183
- Birdshot retinopathy, 516
- Blind-sterile* mutant, 501
- Bmp4*, lens development and, 276
- Bmp7*, lens development and, 276
- Bone morphogenic protein (BMP) receptor 1b, targeting of retinal ganglion cell axons to optic disc and exit from eye and, 385
- Brain
- electroporation and, 626
 - environmental enrichment and, 450
 - retinoic acid actions in, 364–365
- Brain Gene Expression Map (BGEM), search of, for RALDH3 colocalized genes, 370
- Brain-derived neurotrophic factor (BDNF)
- acceleration of visual system development and, environmental enrichment compared with, 453, 454
 - cell death and, 336
 - environmental enrichment and, increase due to, 457–458
 - retinal ganglion cell axon growth and, 401
- Brief-access taste test, 24
- Brightness detection, measurement of, 16, 17f, 18
- Brn-3b, chiasm patterning and, 396–397
- Brn-3b*^{-/-} mice, retinal ganglion cell axon growth ability and, 407–408
- Brn-3b*^{-/-} *Brn-3c*^{-/-} mice, retinal ganglion cell axon growth ability and, 407–408
- Brn-3c, chiasm patterning and, 397
- Brn-3.2, directed growth of retinal ganglion cell axons toward optic disc and, 383–384
- Bruch's membrane, plate 64
- BUB strain, mutation and effect in, 62t
- BUB/BnJ
- auditory evoked brainstem response in, 22
 - taste ability in, 23
- Buried food test, 22
- b-waves, cone-driven, 137, 137f
- BXD Genetic Reference Panel of Mice, 664–665, 666t, 667
- BXSB strain, pattern discrimination in, 18
- C**
- C strain, 13
- Cacna1a* mutations, 100–101
- CaCna1f*^{cmob2} mice, retinal ganglion cell responses in, 179–181, 180f
- Cadherin4, retinal vascularization and, 287
- Calcium
- retinal ganglion cell axon growth ability and, 408
 - synaptic transmission in outer retina and, 177–178
- Calcium currents, in dorsolateral geniculate nucleus, 220
- Calcium imaging
- of direction-selective retinal ganglion cell responses, 598
 - for retinal wave measurement, 343
 - with two-photon microscopy, for ocular dominance plasticity assessment, 441–442, 442f
- Calmodulin kinases (CaMKs), retinal ganglion cell axon growth ability and, 408
- cAMP, retinal ganglion cell axon growth ability and, 408
- cAMP response element-binding protein (CREB), retinoic acid and, 366
- Candida albicans* infections, 508
- Capecchi, Mario R., 35
- Carbohydrates, protein-bound, cataracts and, 499–500
- Carrageenan, subcutaneous injections of, 25
- Caspases, cell death and, 338
- CAST/Ei strain, taste ability in, 23
- CAST/Eij
- hearing and visual abilities in, 15t
 - pattern discrimination in, 18
- Cat3*, 501
- Cat5*, 501
- Cataracts
- age-related, in human and mouse eyes, 588
 - gene expression leading to formation of, 273
 - genetics of, 493–501
 - mouse models for metabolic cataracts and, 499–500
 - mouse models for senile cataracts and, 500
 - mutations affecting lens membranes and, 495–496
 - mutations affecting structural proteins of lens and, 496–499
 - mutations at early stages of lens development and, 493–494, 494f
 - pattern electroretinography and, 124
- β-Catenin, inhibition of lens induction by, 277–278
- Caviness, Vernon, 245
- CBA strains, 13
- avoidance learning in, 28
- CBA/Ca, anxiety-related behavior tasks and, 29
- CBA/Caj, auditory evoked brainstem response in, 22
- CBA/J
- cued and contextual fear conditioning in, 27
 - learning and memory in, 26, 27
 - tactile sensitivity in, 24
 - taste ability in, 23

- CBA strains (continued)
 learning and memory in, 27
 mutation and effect in, 62t
 C57BL/6 and C57BL/6J strain,
 271–272
 anxiety-related behavior tasks and, 29
 auditory evoked brainstem response in,
 22
 circadian photoentrainment and, 210
 conditioned odor preference in, 28
 cones of, anatomy of, 135–137
 diabetes-induced retinal
 neurodegeneration in, 551
 hearing and visual abilities in, 15t, 16
 learning and memory in, 27
 mutation and effect in, 62t
 olfactory ability in, 22, 23
 pain sensitivity in, 25
 pattern discrimination in, 18
 as standard strain, 62
 tactile sensitivity in, 24
 taste ability in, 23, 24
 visual acuity of, 20
 C57BL/6NCrlBR strain
 conditioned odor preference in, 28
 pattern discrimination in, 18
 C57BL/10 strain, 271–272
 C57BR/cdJ strain, auditory evoked
 brainstem response in, 22
 CCCTC binding factor, eye field
 transcription factor regulation by,
 301
 CCL2 protein, cell death inhibition by, 122,
 123f
 CD-1 outbred strain
 conditioned odor preference in, 28
 olfactory ability in, 22, 23
 pattern discrimination in, 18
 CD18, diabetic retinopathy and, 553
 Cell adhesion molecules (CAMs), retinal
 ganglion cell axon guidance through
 visual pathway and, 393
 Cell cycle progression, in retinal progenitor
 cells, *Math5* and, 324
 Cell death
 of developmental cells, retinal ganglion
 cells and, 122
 of endothelial cells, oxygen-induced
 retinopathy and, 293
 of horizontal cells, 149
 in mouse retina, 333–339
 contribution to shaping of retinofugal
 and retinal circuits, 334–336, 335f
 major phases of, 333–334, 334f
 molecules involved in signaling,
 regulating, and executing, 336–339,
 337f
 neurotrophic hypothesis of, 336
 of retinal ganglion cells, 333, 334
 in glaucoma, 485–487, 487f, plate 33,
 plate 34
 matching sizes of interconnected
 neuronal populations and, 335,
 335f
 molecules involved in signaling,
 regulating, and executing, 337, 338
 Cell type-specific promoters
 lineage tracing in retina using, plate 60
 multicolor labeling of retina using, plate
 59
 spatial regulation of gene expression using,
 plate 58
 Cell-labeling techniques, for study of retinal
 ganglion cells, 599
 Cellular retinaldehyde-binding protein
 (CRALBP), in visual cycle, 726
 Cellular retinol-binding protein type 1
 (CRBP1), in visual cycle, 725
 Central nervous system. *See also* Brain
 plasticity of, pattern electroretinographic
 measurement of, 121–122
 Central retinal artery (CRA), anatomy of,
 203–204, 204f
 Central retinal vein, anatomy of, 204
 Centrifugal model of evolution, 6, 7f
 cGMP, retinal ganglion cell axon growth
 ability and, 408
 C3H strains, 13
 avoidance learning in, 28
 conditioned taste aversion in, 29
 mutation and effect in, 62t
 C3HeB/FeJ strain, visual acuity of, 20
 C3H/HeJ strain, cued and contextual fear
 conditioning in, 27
 C3H/He and C3H/HeJ strain
 anxiety-related behavior tasks and, 29
 auditory evoked brainstem response in, 22
 hearing and visual abilities in, 15t, 16
 learning and memory in, 26, 27
 pain sensitivity in, 25
 pattern discrimination in, 18
 tactile sensitivity in, 24
 taste ability in, 23
 visual acuity of, 20
 Chase, Herman, 269
 Chemical nociception, measurement of, 25
 CHI strain, 13
Chlamydia trachomatis infections, 508
 Cholera toxin β subunit (CTB), development
 of eye-specific segregation in lateral
 geniculate nucleus and, 418
 Cholesterol metabolism, cataracts and, 500
 Cholinergic amacrine cells
 mosaic architecture of, 150–151, 151f
 study approaches for, 598
 Chondroitin sulfate proteoglycans (CSPGs)
 control of initial retinal ganglion cell axon
 outgrowth polarity and, 381
 ocular dominance plasticity and, 454–455
 Chorionicapillaris, plate 64
 Choroidal circulation, oxygen delivery to
 retina and, 560–561
 Choroidal neovascularization, gene therapy
 for, 610
 Chromatin, rod development and, 317
 Chronology of mouse visual system
 development, 257–264
 comparison with development in rhesus
 macaque, 261
 future research directions for, 264
 human developmental timing versus,
 261–262, 262f
 model for, 257, 258t, 259, 259f, 260f
 individual variation and observational
 error and, 260–261
 technical and qualitative evaluation of
 model's predictions and, 259–261
 mouse models for, 262–263
 scaling of eye and cortex and, 263–264
 variability of mouse strains and, 262
 Chung peripheral nerve injury model, 25
 Chx10, retinal development and, 303
Chx10-Cre;Rb^{Lux/-} mice
 retinal synaptogenesis in, 317–318, 318f
 rod development in, 313–314
Chx10-Cre;Rb^{Lux/+} mice, retinal synaptogenesis
 in, 317
Chx10-Cre;Rb^{Lux/Lux} mice, rod development in,
 314
Chx10-Cre;Rb^{Lux/Lux};Z/AP mice, rod
 development in, 315
 C12I strain, 13
 Ciliary body, position of, aqueous humor
 outflow and, 129
 Ciliary epithelium
 nonpigmented, 129
 structure of, 129
 Ciliary muscle, 129
 Ciliary neurotrophic factor (CNTF), 613
 retinal ganglion cell axon growth and,
 401
 Ciliary processes, 129, 130f
 Circadian behavior, mouse models for, 215
 Circadian photoentrainment, 207–215
 circadian behaviors in mice and, 207–209,
 208f
 circadian photoentrainment pathway
 neuroanatomy and, 209–210
 intrinsically sensitive retinal ganglion cells
 and, 211–212
 morphology, ontogeny, and functional
 diversity of, 211–212, 212f
 melanopsin and, 213–214
 phototransduction mechanism and,
 213–214
 melanopsin-expressing retinal ganglion
 cell role in circadian
 photoentrainment and, 210–211
 molecular basis of, 214f, 214–215
 mouse as model system for human
 circadian rhythm and, 207
 photosensitivity and, 209
 target brain regions innervated by
 intrinsically photosensitive retinal
 ganglion cells and, 212f, 212–213
 C57L/J strain, auditory evoked brainstem
 response in, 22
 C58/J strain, tactile sensitivity in, 24
Clock gene, 65
 Clomeleon, in bipolar cells, 597
 Cloning of genetic modifiers, 653–655
 chromosomal localization of modified
 traits and, 653–654
 gene expression profiling and, 654–655
 haplotype analysis and, 654
 microarray analysis and, 654–655
 modifier screens using mutagenesis and,
 655

- Cloning of genetic modifiers (continued)
 segregating crosses with multiple strains
 and, 654
- c-Maf*, lens fiber differentiation and, 278
- Coats' disease, 528
- Cochlear vasculature, abnormalities of, in
Ndph knockout mice, 533–534
- Cognitive functions, higher order, vision in
 tasks evaluating, 25
- Collagen I, primary open-angle glaucoma
 and, 482
- Color blindness, gene replacement therapy
 for, 612–613
- Commensal mice, 5
- Compensatory eye movements, 87, 88
 adaptive properties of, 96–99, 97t, 98f,
 99f, 100
- Complete Freund's adjuvant (CFA),
 experimental autoimmune uveitis
 induced by, 515, 520
- Conditioned odor preference, 28
- Conditioned taste aversion, 28–29
- Cone(s), 135–144. *See also* Photoreceptors
 anatomy of, 135–137
 numerosity and retinal disposition and,
 135–136, 136f, plate 2
 retinal connectivity of cones and, 136
 S- and M-opsins and, 136–137
 ultrastructure and, 136
 damaging of, by rod dysfunction, 566
 dim-flash responses of, plate 3
 electroretinographic studies of, 137–139
 a-wave and, 138
 b-wave and, 137, 137f
 functional coexpression of S- and
 M-opsins and, 138–139
 phenotypes of mice with cone
 phototransduction genes inactivated
 and, 138, 138f
 rapid recovery from bleaching stimuli
 and, 138
 functions of, 135
 gap junctions of, 165–166, 166f
 of mouse compared to other mammalian
 species, 36
Nrl^{-/-}, 139, 141–144
 caveats for investigations of, 142
 electrophysiological recordings and,
 141–142, 143f
 histochemical and ultrastructural
 evidence and, 141, 142t
 prospects for studies using, 143–144
 role in scotopic visual pathway, targeted
 ablation to assess, 595–596
 scaling of, 263
 single-cell recordings and, 139, 140f–142f
 spatial vision and, 81–82
- Cone pedicles, 136
- Cone synapses, 136
- Cone visual cycle, 727, 728f, plate 69
- Congenital stationary night blindness
 (CSNB), 650
- Connective tissue, in optic nerve, 202, 203f
- Connexins
 in lens, cataracts and, 495–496, 496f
 as retinal ganglion cell markers, 193
- retinal gap junctions and, 165
 of amacrine cells, 167
 of bipolar cells, 167
 of ganglion cells, 169, 171
 of horizontal cells, 167
 of photoreceptors, 165–166
 in proximal rod pathways, 167–169,
 168f
 retinal waves and, 347
- Cornea
 development of, 697, 698f
 transcription factors involved in, 699f,
 699–703, plate 66
 gene expression in. *See* Gene expression,
 in cornea and lens
 neovascularization of, matrix
 metalloproteinase-9 and, 506
 refractive power of, 73
- Corpus callosum, visual cortex connections
 with, 46–47, 47f
- Coulombre, Alfred and Jane, 269
- Cre expression, in Le-Cre, MLR10, and
 MLR39 strains, plate 12
- Cre recombinases
 cell type-specific regulation using,
 626–627, 629, 630f
 conditional gene alterations using,
 274–275, 275f
 conditional RNAi and, 629–630, 632f
 temporal and cell-type specific regulation
 using, 629, 631f
 temporal regulation using, 626, 627f, plate
 57
- Cre-lox recombinase system
 for drug-controlled gene expression, 600f,
 600–601
 for site-specific recombination, 599–600
- Cre-lox-P system, 274
- Critical periods, experience-dependent
 plasticity and, 473
- Cross-axis adaptation, 98–99, 99f
- Crx*, rod development and, 316
- Cry*, circadian photoentrainment and, 214,
 214f
- Cry^{-/-}* mice, circadian photoentrainment and,
 215
- Cry⁻²* mice, circadian photoentrainment and,
 215
- Cryaa*
 cataracts and, 496, 496f, 588
 mutations of, plate 37
- Cryab*, cataracts and, 496
- Crybal*, cataracts and, 497
- CRYBB2*, cataracts and, 497
- Crybb2*, cataracts and, 497
- Cryg*
 cataracts and, 497–498, 498f
 mutations of, plate 38
- CRYGC*, cataracts and, 498
- CRYGD*, cataracts and, 498
- CRYGD-P23T* mutation, cataracts and,
 498
- Crystallins
 expression in cornea, 705
 in lens, 703–704, 704f, 711–713, 716,
 716f
 posttranslational modification of, 715,
 716
 lens development and, 272
- α -Crystallins
 structure and, plate 67
 cataracts and, 496, 496f
 expression in lens, 703–704, 712f,
 712–713
- β -Crystallins
 cataracts and, 497
 expression in lens, 704, 713
- τ -Crystallins
 cataracts and, 497–498, 498f
 expression in lens, 704, 713
- Cued and contextual fear conditioning, 27
- Cued platform task, for measuring visual
 perception, 110
- Curare, retinal wave blocking by, 345
- Current-clamp recordings, for retinal wave
 measurement, 343
- Cx36 expression, by photoreceptors, plate
 5
- Cyclooxygenase-2 (COX-2) inhibitors,
 herpes simplex virus infection and,
 506
- CYP1B1*
 primary congenital glaucoma and, 483
 primary open-angle glaucoma and, 482
- Cytomegalovirus infections, murine, 509
- Cytoskeletal proteins, cataracts and,
 498–499

D

- DBA/2HaSnm strain, auditory evoked
 brainstem response in, 22
- DBA, DBA/2, and DBA/2J strain, 13
 anxiety-related behavior tasks and, 29
 auditory evoked brainstem response in,
 22
 conditioned odor preference in, 28
 cued and contextual fear conditioning in,
 27
 as glaucoma model, pattern
 electroretinogram application in,
 122–124, 123f
 hearing and visual abilities in, 15t, 16
 learning and memory in, 27
 mutation and effect in, 62t
 pain sensitivity in, 25
 pattern discrimination in, 18
 pigment dispersion syndrome in, 483–485,
 484f
 melanosome contribution to, plate 32
 tactile sensitivity in, 24
 taste ability in, 24
 visual acuity of, 20
- DBA/2NCR1BR strain
 conditioned odor preference in, 28
 pattern discrimination in, 18
- db/db mice
 diabetes in, 550
 diabetes-induced retinal
 neurodegeneration in, 551
- Delayed-type hypersensitivity (DTH)
 responses, 505

- Dendritic arborization, Cre-lox recombinase system for study of, 601
- Dendritic cells, antigen-pulsed, experimental autoimmune uveitis induced by injection of, 516
- Dendritic outgrowth, of horizontal cells, 150, 150f
- Depolarizing bipolar cells (DBC), 136
synaptic transmission in outer retina and, 176f, 176–179, 177t
- Depth of field, measurements of, 80, 80f
- Developmental glaucoma, 483
- Diabetes, adherence in retinal microvasculature of diabetic mouse, plate 47
- Diabetic retinopathy, 547–554
biochemical changes in mouse retinal contributing to development of, 551–553, 552f
in humans, 547
in mice, 547–548, 548f
nonproliferative, mouse models of vascular lesions of, 548–551
chemically induced diabetes and, 548–549, 549f
nondiabetic, developing diabetic-like retinopathy, 550–551
spontaneous diabetes and, 549–550
nonproliferative stage of, 547
proliferative, mouse models of, 553–554
insulin-like growth factor-1 and, 554
oxygen-induced retinopathy and, 553–554
VEGF overexpression and, 554
proliferative stage of, 547
retinal neurodegeneration and, mouse models for study of, 551
- Dickkopf1, eye field formation and, 301
- Diffusers, deprivation myopia from, 82
- Dopaminergic amacrine cells
genetic labeling of, 597–598
mosaic architecture of, 151–153
- Dorsal terminal nuclei (DTN), retinal projections to, 41
- Dorsal visual stream, 373f, 373–374
- Dorsolateral geniculate nucleus (dLGN), 219–229
intrinsic physiology of neurons of, 219–221
calcium currents and, 220
hyperpolarization-activated currents and, 221
oscillations and, 221
potassium currents and, 220–221
sodium currents and, 220, 220t
modulation of retinal signal by, 225–228
burst and tonic responses and, 227–228, 228f
of intrinsic thalamocortical relay cell physiology, 226–227
local geniculate inhibition and, 225–226, 226f
presynaptic, 225
output of, 221–225
retinogeniculate inputs and spatial information and, 221–223, 222f–224f
retinogeniculate inputs and temporal information and, 223–225
retinal projections to, 40, 44–45
- Dräger, Ursula, 245
- Drug-controlled gene expression
Cre-lox recombinase system for study of, 600f, 600–601
reversible, 601
- ## E
- Early-life stimulation, neuronal and behavioral development and, 450–451
Efnb2, retinal vascularization and, 288
Egr-1 knockout, refractive errors in, 83
Egr-1 mRNA, regulation of, 82
Eicosanoids, diabetic retinopathy and, 553
- Eight-arm radial maze, 18
- Electrical stimulation, retinal ganglion cell axon growth and, 404–405
- Electroporation, 621–631
controlling expression following, 626–630
cell type-specific regulation using specific promoters and, 626–627, 628t, 628f–630f, 629
conditional RNAi and, 629–630, 632f
temporal and cell type-specific regulation and, 629, 631f
temporal regulation and, 626, 627f
future applications of, 630–631
method of, 621–626
in vitro, retinal, 623, 625f, 625–626, plate 55, plate 56
in vivo, comparison to other in vivo gene delivery methods, 621
in vivo, brain, 626
in vivo, retinal, 621–623, 622f–624f, plate 50, plate 51, plate 52, plate 53, plate 54
- Electroretinogram (ERG)
with cone phototransduction gene inactivation, 138, 138f
functional features of cones and, 138, 138f
- Elevated plus maze, 29
- Elevated zero maze, 29
- ELOVL4* gene, age-related eye diseases and, 582, 584–588
- ELOVL4* mice, 613, 638
- Embryonic stem cells, in vitro generation of retinal ganglion cells from, 329–330
- Encephalitis, viral, 509
- Endostatin, anti-angiogenic properties of, 610
- Endothelial cells, apoptosis of, oxygen-induced retinopathy and, 293
- Endothelial tip cell guidance, retinal vascularization and, 287
- Endotoxin-induced uveitis (EIU), 513–515, 514f
histology of, plate 39
- Environmental enrichment
plasticity and, 449–459
early-life stimulation effects on neuronal and behavioral development and, 450–451
neural consequences of environmental enrichment and, 450
visual system development and, 451–459, 452f, 454f, 455f, 457f, 459f, plate 28, plate 29, plate 30
temporal phases during development controlled by environmental richness and, 458, 459f
- Enzyme replacement therapy, 639
- EphB2, targeting of retinal ganglion cell axons to optic disc and exit from eye and, 383f, 383–385
- EphB3, targeting of retinal ganglion cell axons to optic disc and exit from eye and, 383f, 383–385
- Ephb4*, retinal vascularization and, 288
- Ephrin(s), targeting of retinal ganglion cell axons to optic disc and exit from eye and, 383f, 383–385
- Ephrin ligands, retinal vascularization and, 288
- Ephrin-B1/ephrin-B2, retinal ganglion cell axon divergence at chiasm and, 393, 394f, 395
- Erythropoietin, proliferative retinopathy and, 292–293
- Esi-1/Elf3, in cornea and lens development, 703
- Ethylnitrosourea (ENU), as mutagenic agent, 493
- Evans, Martin J., 35
- Evolution
centrifugal model of, 6, 7f
of house mice, 6–8, 7f
sequential (linear) model of, 6–7, 7f
- Excitatory postsynaptic potentials (EPSPs), in lateral geniculate nucleus, 420, 421f, 422, 424
- Experience-dependent visual cortical plasticity, 465–473
adult ocular dominance plasticity and, 472–473, 474f
mechanisms of ocular dominance shift in mice and, 468–471
monocular deprivation in juvenile mice and, 463, 469f, 470f
stimulus-selective response potentiation and, 471–472, 472f
visually evoked potential recording technique and, 466, 467f, 468
- Experimental autoimmune uveitis (EAU)
associated with anti-tumor response to melanoma antigen, 517
histology of, plate 39
in human lymphocyte antigen transgenic mice, 516
induced by active immunization with retinal antigen, 515, 516t, 517f
induced by adoptive transfer of antigen-specific T cells, 515
induced by injection of antigen-pulsed dendritic cells, 516

- Experimental autoimmune uveitis
(continued)
in mice expressing a transgenic target antigen in the retina, 515–516
pathogenesis of, critical checkpoints in, plate 39
spontaneous, 516–517
- Expressed sequence tags (ESTs), 662–663
- ey1 mutation, 269
- ey2 modifier genes, 269
- Eye, of mouse compared to other mammalian species, 35
- Eye field transcription factors (EFTFs), 299–302
expression in retinal progenitor cells, 299, 302–303
interaction of, 300
regulation of, 300–301
transcription targets of, 301–302
- Eye movements, 87–102
after-nystagmus and velocity storage integrator and, 94–96, 96f
angular vestibulo-ocular reflex and, 88–91, 89f, 90f
compensatory, 87, 88
adaptive properties of, 96–99, 97t, 98f, 99f
control of, importance of, 87
in foveate and avoveate mammals, 87
gaze holding and velocity-to-position neural integrator and, 96
gaze-shifting, 87–88
nystagmus and, fast phases of, 99–100, 100f
off-vertical axis stimulation and, 93–94, 94f
optokinetic reflex and, 91, 91f
otolith-ocular reflexes and, 91–93, 92f
rapid, saccade-like, 233
electrically induced, in mice, 235–238, 237f
measurement of, 233–234, 234f
spontaneous, in mice, 234f, 234–235, 236f
reasons for studying, 87
recordings of, applications of, 100–101
visual-vestibulo-ocular reflex and, 89f, 89–91, 90f
- Eyeless*. See *Pax6*
- F**
- Fear conditioning, cued and contextual, 27
- Fetal loss, in *Ndph* knockout mice, 534–535
- Fgfr signaling, lens development and, 276–277
- Field mice, 5
- Filensin, cataracts and, 498–499
- Fixation mechanism, 88
- Fluorescence resonance energy transfer (FRET), 597
- Fluorescent reporters
under control of *Thy-1* promoter, 598
subcellular spatial resolution using, 597
- Fontana's spaces, 130
- Force-choice apparatus, two-alternative, for visual acuity measurement, 18, 20
- Forced choice discrimination task, for measuring visual perception, 109
- Formalin test, 25
- Forward genetics approach, 66–67, 67f
- Fox*, cataracts and, 494
- Foxd1*, chiasm patterning and, 396
- FOXE3, in cornea and lens development, 701
- Foxe3*, lens development and, 277
- Foxg1*, chiasm patterning and, 396
- Foxn4*, *Math5* repression in retinal progenitor cells and, 326
- Frs2α*, lens development and, 277
- Fungal infections, mouse models of, 508
- FVB/N strain, 15
FVB/NJ
anxiety-related behavior tasks and, 29
auditory evoked brainstem response in, 22
avoidance learning in, 28
hearing and visual abilities in, 15t
pain sensitivity in, 25
pattern discrimination in, 18
visual acuity of, 20
mutation and effect in, 62t
- FVBS/Ant strain, 15
- G**
- GABAC* null mice, refractive errors in, 83
- GABA_CR*, inhibition mediated by
alteration of visually and electrically evoked responses of ON-center retinal ganglion cells by, 183–184, 184f
control of output of bipolar cell synaptic output by, 182–183
- GABAergic* neurons, of superior colliculus, 239
- GAD67 (Gad)*-GFP knock-in mice, *GABAergic* neurons in, 239
- Galactose feeding, diabetes and, 550
- $\alpha(1,3)$ -Galactosyltransferase, cataracts and, 499
- Ganglion cell(s), gap junctions of, 169, 170f, 171
functional role of, 171
- Ganglion cell layer (GCL), 635, 636f
- GAP-43*, retinal ganglion cell axon guidance through visual pathway and, 392f, 393
- Gap junctions, 165–171
of amacrine cells, 167
of bipolar cells, 167
transgenic mice to study, 596–597
ganglion cell coupling and, 169, 170f, 171
functional role of, 171
of horizontal cells, 166f, 166–167
of photoreceptors, 165–166, 166f
in proximal rod pathways, 167–169, 168f
retinal waves and, 346–347
- Gaze holding, oculomotor neural integrator and, 96
- Gaze-shifting movements, 87, 88
- GCI-/-* mice, as model for Leber congenital amaurosis, 611
- Gdf3/Myostatin*, control of retinal progenitor cell proliferation by, 328
- Geminin, eye field transcription factor regulation and, 302
- Gene(s). See also *specific genes*
controlling vision, finding, 62–63, 64f, 65f
epistatic interaction between, 651–653, 652t
- Gene deletion, to define role of cholinergic signaling by starburst amacrine cells, 598
- Gene expression, 685–694, 686f
analysis of
correlation of retinal pigment epithelium gene expression and retinal vascularization and, 692–693
isolation of retinal pigment epithelium and, 688, 689f, 690f, 690–691
isolation of retinal vasculature and subsequent gene expression studies and, 688, 689f, 691–692
study methods for, 686–687
transgenics in, 692
in cornea and lens, 697–706
cornea and lens development and, 697, 698f
large scale analyses of, 698–699
regulation of specific genes and, 703–705
transcription factors and, 699f, 699–703, plate 66
degeneration networks by expression profiling of photoreceptors from *rd* mice and, 679–680
drug-controlled
Cre-lox recombinase system for study of, 600f, 600–601
reversible, 601
expression profile of mRNA from whole mouse retinas at different postnatal developmental stages and, plate 65
inducible, in differentiated Müller glia, plate 61
mapping of, for ocular dominance plasticity assessment, 442–443
in mouse eye, 662
in retinal pigment epithelium
correlation of retinal pigment epithelium gene expression and retinal vascularization and, 692–693
isolation of retinal pigment epithelium and, 688, 689f, 690f, 690–691
in retinal vasculature
correlation of retinal pigment epithelium gene expression and retinal vascularization and, 692–693
isolation of retinal vasculature and subsequent gene expression studies and, 688, 689f, 691–692
spatial regulation of, using cell type-specific promoters, plate 58
Gene expression profiling, 654–655

- Gene targeting methods, 594–595, 595f
- Gene therapy
 antiangiogenic, 607
 neurotrophic factor, 613
 for retinal degeneration, 675
 vectors for, 605
 adenoassociated virus. *See*
 Adenoassociated virus (AAV) gene
 therapy
- Gene transfer methods, 593–594, 594f. *See*
 also Electroporation
- Genetic modifiers
 as cause of phenotypic variation, 651–653,
 652t
 retinal degeneration and, 652–653
 cloning of, strategies for, 653–655
 chromosomal localization of modified
 traits and, 653–654
 gene expression profiling and, 654–655
 haplotype analysis and, 654
 microarray analysis and, 654–655
 modifier screens using mutagenesis and,
 655
 segregating crosses with multiple strains
 and, 654
- Genetic networks in mouse eye, 667f,
 667–668
 microarray methods and, 669
- Genetic tagging technique, to ablate
 starburst amacrine cells, 598
- Genomics, glaucoma therapy and, 488
- GFP, expression in rods, plate 63
- Ggta1*, cataracts and, 499
- Gja3*, cataracts and, 495–496
- Gja8*
 cataracts and, 496, 496f, 588
 mutations of, plate 37
- Glaucoma
 future prospects for new therapies for,
 487–488
 genomics and proteomics and, 488
 neuroprotection as, 487–488, 488f
 genetic component in, 479
 human clinical research on, pattern
 electroretinography in, 124
 mouse models of, 479–489
 accuracy of intraocular pressure
 measurements in, 480
 advantages of, 479
 of developmental glaucoma, 483
 experimentally induced glaucoma and,
 481
 pattern electroretinogram application
 in, 122–124, 123f
 of pigmentary glaucoma, 483–485,
 484f
 of primary congenital glaucoma, 483
 of primary open-angle glaucoma,
 481–482
 similarity between mouse and human
 structures relevant to, 479–480
 mutagenesis and new models of, 488–489
 neurodegeneration and, 485, 485f
 optic nerve excavation in, prevention by
 radiation treatment, plate 35
 overview of, 479
- primary open-angle
 models of, 489
 mouse model of, 481–482
- retinal ganglion cell death in
 regional patterns of, 485–486, plate 33
 soma death and axon degeneration and,
 486–487, 487f
- treatment of, 644
 future prospects for new therapies for,
 487–488
- Glaucomatous optic neuropathy, retinal
 ganglion cell axon regeneration in,
 409
- Gli family, control of retinal progenitor cell
 proliferation by, 329
- Glial cell(s), in optic nerve, 201–202
- Glial cell line-derived neurotrophic factor
 (GDNF), 613
 retinal ganglion cell axon growth and, 401
- Glial fibrillary acidic protein-green
 fluorescent protein (GFAP-GFP)
 transgenic mice, 287
- Glucagon amacrine cells, in mouse versus
 chicken eye, 82–83
- GluR6, signaling through, 596
- Glycine receptor $\alpha 2$, photoreceptor
 development and, 305
- Gnao1^{tm1Lhi}* mice, control of depolarizing
 bipolar mGluR6 signaling cascade in,
 178–179, 179f
- Gpmb^{R130X}*, pigmentary glaucoma and, 483
- Grm6^{sub4}* mice
 control of depolarizing bipolar mGluR6
 signaling cascade in, 178–179, 179f
 retinal ganglion cell responses in, 181
- Grm6^{Tm1Nak}* mice
 control of depolarizing bipolar mGluR6
 signaling cascade in, 178–179, 179f
 retinal ganglion cell responses in, 181
- Growth, of retinal ganglion cell axons. *See*
 Retinal ganglion cells (RGCs), axon
 growth and regeneration of
- Growth factors. *See also specific growth factors*
 lens and, 273
 retinal vascularization and, 286–287
- Growth of mouse eye, 74
- Guidance molecules, retinal vascularization
 and, 288
- ## H
- Habituation-discrimination test, 22–23
- Habituation-dishabituation test, 22–23
- Hamilton Eye Institute Mouse Database
 (HEIMED), 664
 BXD Genetic Reference Panel of Mice
 and, 664–665, 666t, 667
 genetic networks in eye and, 667, 667f
 quantitative trait locus mapping in,
 668–669, 670
- Hargreaves test, 24, 25
- Hartmann-Shack aberrometry
 optical aberration measurement using,
 79f, 79–80
 spherical aberration found on, 75–76
- Head tilt mice, 101
- Hearing, in mice, 15t
- Hearing ability, measurement of, 20, 22
- Hearing loss, in *Ndph* knockout mice,
 533–534
- Heat shock transcription factors
 cataracts and, 496–497
 in cornea and lens development, 702
- Hematopoietic stem cells (HSCs), retinal
 vascularization and, 289
- Herpes simplex virus (HSV) infections, 505
- Herpes stromal keratitis (HSK), 505–506
- Hes1
 eye field formation and, 301
 retinal development and, 324
- Hes5, eye field formation and, 301
- Hind limb denervation, as model of
 anesthesia dolorosa, 25
- Hmgn1, in cornea and lens development,
 701
- Horizontal cells
 development of, Rb and, 318
 gap junctions of, 166f, 166–167
 mosaic architecture of, 148–150, 149f,
 150f
- Hot-plate test, 24–25
- House mice, 5
- Hsf4*, cataracts and, 496–497
- Hspg2*, cataracts and, 499–500
- Human genome, 660
- Human leukocyte antigen (HLA) transgenic
 mice, experimental autoimmune
 uveitis in, 516
- Hyperoxia, depletion-induced, lack of
 oxygen supply to outer retina and,
 565–566
- Hyperpolarizing bipolar cells (HBCs), 136
 synaptic transmission in outer retina and,
 176f, 176–179, 177t
- Hypopigmented mice, 61
- ## I
- I- κ B- ζ , in cornea and lens development,
 702
- I/LnJ mice, auditory evoked brainstem
 response in, 22
- Immunoprecipitation (IP), visual cycle
 protein interactions and, 729
- Impact-rebound (I/R) tonometry, 480
- Inbred strains
 genetic variability in, 668
 power of, 668
 used for research, 13
 on lens, 271–272
- Inducible nitric acid synthase (iNOS),
 diabetic retinopathy and, 553
- Inducible RNAi, in retina, plate 62
- Infantile neuronal ceroid lipofuscinosis
 (INCL), gene replacement therapy
 for, 612
- Infectious eye diseases, 505–509
 bacterial, 506–508
 fungal, 508
 herpetic, 505–506
 parasitic, 508–509
 retinal, mouse models of, 509

Inferometry, low-coherence, 77–79, 78f
 Infrared photoretinography, 74–76, 76f, 77
 Inhibitory postsynaptic potentials (IPSPs), in lateral geniculate nucleus, 420, 421f
 Inner plexiform layer (IPL)
 dendrites in, 194
 lateral inhibition in, 175
 Insulin-like growth factor (IGF)
 cell death and, 336
 retinal ganglion cell axon growth and, 401
 Insulin-like growth factor-1 (IGF-1)
 eye field formation and, 301
 overexpression of, 554
 visual cortical plasticity and, 456
 Interferometer, Michelson, 79
 Interferon- τ (IFN- τ)
 experimental autoimmune uveitis and, 520
 Pseudomonas aeruginosa infections and, 507
 Intergeniculate leaflet (IGL), retinal projections to, 40, 41
 Interlaminar connections, in superior colliculus, 239, 240f
 Interleukin-1 β (IL-1 β), diabetic retinopathy and, 553
 Interleukin-8 (IL-8)
 proliferative retinopathy and, 292, 293
 Pseudomonas aeruginosa infections and, 507
 Interphotoreceptor retinoid-binding protein (IRBP)
 experimental autoimmune uveitis induced by, 515
 in visual cycle, 726
 Intracellular adhesion molecule-1 (ICAM-1), diabetic retinopathy and, 553
 Intraocular pressure (IOP)
 aqueous humor outflow and, 131
 measurement of, accuracy of, 480
 Ischemic optic neuropathy, retinal ganglion cell axon regeneration in, 409
 Islet2
 retinal ganglion cell axon divergence at chiasm and, 395
 as retinal ganglion cell marker, 193
 Isoelectric focusing (IEF), in proteomics, 713–714
 Isomerohydrolase, in visual cycle, 723–724

J

Jackson Laboratory, 13, 581–582
 Junctional adhesion molecule-B (JAM-B), as retinal ganglion cell marker, 193
 Juxtacanalicular connective tissue (JCT), 131, 131f

K

Keratins, expression in cornea, 705
 Keratitis, stromal, herpes, 505–506
 Keratocan, expression in cornea, 705
 Keratomycosis, 508
 Kessler, Paul Leonhard, 270
 Kinases, cell death and, 338
 KKAY mouse
 diabetes in, 550

diabetes-induced retinal neurodegeneration in, 551
 Knockout mouse models, 65, 635–645. *See also specific models*
 anterior chamber cell types and, 644–645
 developers of, 35
 for lens research, 273–274
 P7, plate 42
 refractive errors in, 83
 retinal cell types and, 635, 636f, 637
 retinal pigment epithelium and, 637–639, 639f
 vascular cell types and, 639–643, 641f, 643f

L

Lac repressor-lac operator system, for study of retinal ganglion cells, 599
 Lamina cribrosa (LC), in glaucoma, 485–486
 Lamina cribrosa region, of optic nerve, 201, 202f
 Lang, Richard, 275
 Lateral geniculate nucleus (LGN)
 cellular composition of, 419
 differentiation of neurons of, 419
 dorsal. *See* Dorsolateral geniculate nucleus (dLGN)
 excitatory responses in, 420, 422, 424
 eye-specific segregation in, development of, 415–416, 416f, 417f, 418
 inhibitory responses in, 422
 retinal ganglion cell projections to, 192
 synaptic connectivity patterns in, 422, 423f, 424
 synaptic remodeling in, 429–430, 430f, 430–431, 431f
 activity and, 431–432
 comparison with remodeling in other regions of visual system, 433–434
 cortical critical period in, 433
 genes involved in, 434–435
 plasticity in lateral geniculate nucleus and, 432–433
 superior colliculus and, 433–434
 vision-sensitive phase of, 433
 Lateral terminal nuclei (LTN), retinal projections to, 41
 Lateromedial area, extrastriate, intracortical connections of, plate 9, plate 10
 Lathrop, Abbie, 13
 Learning tasks, 25–29
 visually dependent, 25–28
 visually independent, 28–29
 Leber congenital amaurosis (LCA), gene replacement therapy for, 611–612
 Lecithin:retinol acyltransferase (LRAT), in visual cycle, 723
 Le-Cre strain, Cre expression in, plate 12
 Lens, 267–279
 cell proliferation in, 270
 connexins in, cataracts and, 495–496, 496f
 crystallins in, 703–704, 704f, 711–713, 716, 716f
 posttranslational modification of, 716

posttranslational modifications and, 715
 development of, 267, 268f, 697, 698f
 transcription factors involved in, 699f, 699–703, plate 36
 epithelial cells of, 267
 fiber cells of, 267
 function of, 267–268
 gene expression in. *See* Gene expression, in cornea and lens
 lens transplantation experiments and, 270
 membranes of, mutations affecting, 495–496
 morphological descriptors of, 270
 mutations affecting structural proteins of, cataracts and, 496–499
 proteomics of, 711–718, 716f
 crystallins and, 711–713, 716
 posttranslational modifications and, 715
 refractive power of, 73
 research on development of
 conditional gene alterations using Cre recombinase and, 274–275, 275f
 customizing mouse genome for, 273–274
 differences among mouse strains and, 271–272
 historical background of, 268–269
 lens complementation system for, 274
 lens fiber differentiation and, 278
 molecular biology and, 272
 mouse and human lenses compared and, 270–271
 mouse lens induction and, 275–278, 276f
 murine models for, 269–270
 nonmurine model systems for, 268–269
 transgenic mice for, 272–273
 structure of, 267
 Lens complementation system, 274
 Leukemia inhibitory factor (LIF), retinal vascularization and, 287
 Leukocytes
 adherence in retinal microvasculature of diabetic mouse, plate 47
 mouse model of oxygen-induced retinopathy and, 293–294
Lhx2, as eye field transcription factor, 300
 Lid suture, deprivation myopia from, 82
 Liegeois, Nanette, 274
 Light
 acceleration of photoreceptor degeneration by, lack of oxygen supply to outer retina and, 566
 continuous, refractive development and, 82
 raising of oxygen levels in outer retina by, 565
 responses to exposure to, *Rpe65* alleles and, 650–651
 retinal degeneration induced by, 16, 573
 mouse strains with, 16
 Light-dark transition test, 29
Lim2, cataracts and, 495
 Lineage tracing, Cre-lox recombinase system for study of, 601

- Linear control systems analysis, 88n
 Linear model of evolution, 6–7, 7f
 Linear vestibulo-ocular reflex (IVOR), 88
Lip12, cataracts and, 588
 Lipofuscin, in retinal pigment epithelium, 539–544, 540f, 638
 autofluorescence of, plate 44
 inhibiting formation of fluorophores and, targeting visual cycle for, 543f, 543–544
 Leu450Met variant in murine Rpe65 associated with, 542–543, 543f
 Rpe65^{-/-} mice and, 539–540, 540f
 Stargardt macular degeneration and *Abca4/Abcr* null mutant mice and, 540–542, 541f
 Liquid chromatography, in proteomics, 714
Listeria monocytogenes infections, 508
 Little, Clarence Cook, 13, 269
 Long-term depression (LTD)
 AMPA receptors and, 470
 aVOR gain and, 100
 ocular dominance shift and, 468
 Long-term potentiation (LTP)
 mechanism for, 471
 ocular dominance shift and, 468
 retinoic acid and, 366
Lop10, cataracts and, 588
 Low-coherence interferometry, 77–79, 78f
Lrat^{-/-} mice, 723
 Lucentis (ranibizumab), for age-related macular degeneration, 607
 Lurcher mice, 101
 Lysosomal storage disease, gene replacement therapy for, 612
- M
- Mab21/2*, lens development and, 277
 MacDowell, E. Carlton, 13
 macrophage inhibitory protein-2 (MIP-2), herpes simplex virus infection and, 506
 Macrophages, mouse model of oxygen-induced retinopathy and, 294
 Macugen (pegaptanib), for age-related macular degeneration, 607
 Macular degeneration
 age-related, gene therapy for, 607
 Stargardt, in *Abca4/Abcr* null mutant mice, 540–542, 541f
Maf, cataracts and, 494
 Maf transcription factors, in cornea and lens development, 702
 Magnetic search coil oculoigraphy, 89
 Major histocompatibility complex I (MHC I)
 antigen, lateral geniculate nucleus synaptic remodeling and, 434–435
 MA/MyJ strain, auditory evoked brainstem response in, 22
 Mann, Ida, 269
 Mass spectrometry
 in proteomics, 714
 visual cycle protein interactions and, 729
- Maternal care, neuronal and behavioral development and, 451, 455–456, 458
Math5
 circadian photoentrainment and, 210, 211–212
 regulation of expression of, 325–327
 of duration of expression, 325–326, 326f
 math5 activation in retinal progenitor cells and, 325
 repressing expression in other retinal progenitor cells and, 326–327
 retinal ganglion cell development and, 324–325
 activation of retinal ganglion cell fate and, 325
 cell cycle progression and, 324
 retinal ganglion cell competence and, 324
 suppression of non-retinal ganglion cell fates and, 324–325
 retinal ganglion cell differentiation downstream of, regulation of, 327–329
 control of retinal progenitor cell proliferation by retinal ganglion cell-secreted signaling molecules and, 328–329
 genes regulated by Pou4f2 and, 327–328
 regulation of retinal ganglion cell axon outgrowth and pathfinding and, 328
 transition for retinal ganglion cell competence to retinal ganglion cell commitment and, 327
- Math5*
 expression in retinogenesis, plate 16
 retinal ganglion cell development and, 194
 Matrix metalloproteinase-9 (MMP-9), corneal neovascularization and, 506
 Mechanical sensitivity, von Frey filament test of, 24
 Medial terminal nucleus (MTN), retinal projections to, 41
 Melanoma antigen, anti-tumor response to, uveitis associated with, 516
 Melanopsin, 213–214
 phototransduction mechanism and, 213–214
 Melanosomes, DBA/2J pigment dispersion and, plate 32
 Membrane currents, in dorsolateral geniculate nucleus, 220f, 220–221
 Memory tasks
 visually dependent, 25–28
 visually independent, 28–29
 Mesencephalon, visual cortex connections with, 46
 Michelson interferometer, 79
 Microarray analysis, 654–655, 663–667
 BXD Genetic Reference Panel of Mice and, 664–665, 666t, 667
 defining genetic networks in, 669
 expression profiling using, 675–676
 gene expression and, 686–687
- Hamilton Eye Institute Mouse Database and, 664
 Microarray-based technologies, glaucoma therapy and, 488
 Microglia, mouse model of oxygen-induced retinopathy and, 293–294
 Microphthalmia, in C57BL mice, 271
Mip, cataracts and, 495
 MLR10 mice, 274–275
 Cre expression in, plate 12
 MLR39 mice, 275
 Cre expression in, plate 12
 MOLF/Eij strain
 anxiety-related behavior tasks and, 29
 hearing and visual abilities in, 15t
 pattern discrimination in, 18
 visual acuity of, 20
 Monocular deprivation (MD)
 in juvenile mice, effects of, 468, 469f, 470f
 ocular dominance shift and, 470–471
 ocular dominance studies and. *See* Ocular dominance (OD) plasticity
 M-opsin, cone, expression of, 136, 138–139
 Morris water maze, 25–26, 26f
 for measuring visual perception, 109–110
 Mosaic architecture, of retina, 147–153
 cholinergic amacrine cells and, 150–151, 151f
 development of, 147–148, 148f
 dopaminergic amacrine cells and, 151–153
 horizontal cells and, 148–150, 149f, 150f
 Mouse genome, 660–662
 sequence differences among mice and, 660–662, 661f, 662t
 Mouse hepatitis virus (MHV) infections, 509
 Mouse models. *See also specific models*
 advantages of, 363
 historical background of, 61–62, 62t
 mutant. *See also specific models*
 eye movements and, 100–101
 of synaptic transmission in outer retina, 176f, 176–179, 177t
Mox-Cre;Rb^{Lox/Lox} mice, rod development in, 314
 Mucopolysaccharidosis type VII (MPS VII), gene replacement therapy for, 612
 Müller glia, differentiated, inducible expression in, plate 61
 Multielectrode arrays (MEAs), for retinal wave measurement, 343
 Murine coronavirus infections, 509
 Murine cytomegalovirus infections (MCMV), 509
Mus, 3–8
 phylogenetic relationships in genus, 8
 subgenera of, 3–6, 4f
Mus booduga, 5, 8
Mus caroli, 8
Mus cervicolor, 5, 8
Mus Coelomys, 3–5, 8
Mus cookii, 8
Mus crociduroides, 5
Mus cypriacus, 6
Mus famulus, 5, 8
Mus fernandoni, 5

- Mus fragilicauda*, 5, 8
Mus lepidoides, 5–6, 8
Mus macedonicus, 6, 8
Mus mayori, 5
Mus Mus, 3–4, 8
Mus mus castaneus, 6, 7, 8
Mus mus domesticus, 6–7, 8
Mus mus gentilulus, 6, 7, 8
Mus mus musticus, 6, 7, 8
Mus musculus, 3, 5, 6, 8
 evolutionary history of, 6–8, 7f
Mus Nannomys, 3, 5, 8
Mus nitidulus, 5, 8
Mus pahari, 5
Mus phillipsi, 5
Mus plathythrix, 5
Mus Pyromys, 3–4, 5, 8
Mus Sensu stricto, 5
Mus shortridgei, 5
Mus spicilegus, 6, 8
Mus spretus, 6, 8
Mus terricolor, 8
Mus vulcani, 5
Mutagenesis, modifier screens using, 655
Mutant mouse models, 14. *See also specific models*
 eye movements and, 100–101
 of synaptic transmission in outer retina, 176f, 176–179, 177t
 postsynaptic mouse mutants and, 177t, 178–179, 179f
 presynaptic mouse mutants and, 177t, 177–178
Muthukkaruppan, V., 269–270
Myelinated portion, of optic nerve, 201, 202f
Myelinogenesis, of optic nerve, 201–202
MYO7A, age-related eye diseases and, 584
Myocilin (*MYOC*), in primary open-angle glaucoma, 481–482
Myopia, deprivation
 induced by frosted diffusers, 82
 from lid suture, 82
- N
- nAChR subunits, retinal waves and, 345–346
Nakano cataract, 501
Nance-Horan syndrome (NHS), 499
Nbn gene, senile cataracts and, 500
NDP, 528
 evolutionary conservation and expression pattern of, 528, 529f
Ndph, 529–530
Ndst1, lens development and, 277
Negative masking, circadian photoentrainment and, 210
Neo-antigen-driven experimental autoimmune uveitis, 515–516
Neovascularization
 choroidal, gene therapy for, 610
 corneal, matrix metalloproteinase-9 and, 506
 retinal
 gene therapy for, 607, 609–610
 limitation by laser burns, 565
 protection against, by degradation of photoreceptors, 565
Netrin-1
 regulation of retinal ganglion cell axon exit from eye by, 383f, 384
 retinal ganglion cell axon guidance through visual pathway and, 392, 392f
NEUBank, 663
Neurodegeneration, glaucoma and, 485, 485f
Neurofilament H, antibodies against, as retinal ganglion cell marker, 193
Neuroglobin, retinal oxygen consumption and, 562
Neuronal plasticity, RALDH3 colocalization with markers for, 368, 369f
Neuronal tissue, in optic nerve, 201
Neuron-specific enolase (NSE), cell death and, 337
Neuropathic pain, measurement, 25
Neuroprotection, for glaucoma treatment, 487–488, 488f
Neurotrophic factor gene therapy, 613
Neurotrophin(s), cell death and, 336
Neurotrophin-3
 postnatal cortical maturation patterns defined by, 369–370, 370f
 RALDH3 relationship with, 368–369, 369f
Neutrophils, *Pseudomonas aeruginosa* infections and, 507
Nhs1 protein, cataracts and, 499
Night blindness, stationary, congenital, 650
NMDA, excitatory lateral geniculate nucleus responses and, 420
NMDA receptors (NMDARs), 223–225
 ocular dominance shift and, 469
 in reticulogeniculate synapses, 431, 439
NMDA-type glutamate receptor antagonist, stratum griseum intermediale burst generation and, 240
nob knockout mice, refractive errors in, 83
NOD strain, diabetes in, 550
NOD/LtJ strain, auditory evoked brainstem response in, 22
Noggin, eye field formation and, 301
Nonpigmented ciliary epithelium (NPE), 129
Nop, cataracts and, 497
NOR/LtJ strain, auditory evoked brainstem response in, 22
Norrie, Gordon, 527
Norrie, function of, 528–529
Norrie disease, 527–535
 clinical background of, 527
 extraocular features of, 527
 knockout mouse model for, 529–530
 abnormal retinal vascular development in, 530–531, 531f, 532f
 ectopic norrin expression in lens and, 534
 fetal loss in homozygous females and, 534–535
 hearing loss and abnormal cochlear vasculature in, 533–534
 hyaloid vessel regression versus angiogenesis of retinal blood vessels in, 532, 533f
 phases of, 532–533
 retinal physiology of, 530
 sprouting angiogenesis failure in, 531–532
 molecular basis of, 527–528
 NDP gene conservation and expression pattern and, 528, 529f
 norrin and, 528–529
 transgenic mouse line with norrin overexpression in lens and, 534
Norrin, 528
 ectopic expression in lens, rescue of knockout phenotype by, 534
 overexpression in lens, transgenic mouse line with, 534
Norrin knockout mice, hematoxylin-eosin-stained sections of whole eyes from, plate 43
Notch pathway
 eye field formation and, 301
 retinogenesis regulation and, 303–304
Npp, 501
Nr-CAM, retinal ganglion cell axon divergence at chiasm and, 394f, 395
Nr2e3, rod development and, 316
Nr2e3, photoreceptor development and, 304–305
NRL, gene profiling of purified photoreceptors and, 676, 677f
Nrl, photoreceptor development and, 304–305
Nrl, rod development and, 316
Nrl^{-/-} knockout mice
 as model for central field loss, 613
 photoreceptors of
 caveats for investigations of, 142
 cones as, 139, 141–144
 cone-specific genes and their molecular function and, 143–144
 differentiation of, 143
 mouse cone protein biochemistry and, 144
 prospects for studies using, 143–144
Nuclear posterior polar opacity, 501
Nucleus of the optic tract (NOT), retinal projections to, 41
Null mutation. *See* Knockout mouse models
Nystagmus
 fast phases of, 99–100, 100f
 off-vertical axis rotation engendering, 94
 optokinetic, velocity storage integrator and, 95f, 95–96
 optokinetic after-nystagmus and, 94
 postrotatory, 94
Nyx^{nob} mice
 control of depolarizing bipolar mGluR6 signaling cascade in, 178–179, 179f
 retinal ganglion cell responses in, 181
NZB/BINJ strain, taste ability in, 23
NZW strain, mutation and effect in, 62t
NZW/LaJ strain, photoreceptor response damage by light and, 575, 577

O

- ob/ob mice, diabetes in, 550
- Ocular dominance (OD), mapping of, plate 26
- Ocular dominance (OD) plasticity, 439–446.
See also Visual cortical plasticity, experience-dependent
- adult, 443, 444f, plate 27
- enhancement by prior experience, 445f, 445–446, 446f
- mechanisms of, 443–445
- behavioral correlates of, 447
- chondroitin sulfate proteoglycans and, 454–455
- extended duration visually evoked potentials for assessment of, plate 31
- juvenile, mechanisms of, 443–445
- methods for assessing, 439–443
- calcium imaging with two-photon microscopy as, 441–442, 442f
- mapping of gene expression as, 442–443
- optical imaging as, 440f, 440–441, 441f
- single-unit recordings as, 439
- visually evoked potentials as, 439–440
- ocular dominance column plasticity and, 465–466
- Ocular hypertension, treatment of, 644
- Oculography, applications of, 101
- Oculomotor control, importance of, 87
- Oculomotor neural integrator, 96
- Odor discrimination ability, measurement of, 22–23
- Odor preference, conditioned, 28
- Off-vertical axis rotation (AVOR), 93–94, 94f
- Olfactory ability, measurement of, 22–23
- Olfactory tubing maze, 28
- Oligodendrocytes, in optic nerve, 202
- Olivary pretectal nuclei (OPT), retinal projections to, 41
- ON and OFF pathways in mouse retina, 353–360
- cellular and synaptic structure of, 353–354, 354f
- segregation of
- mechanisms of, 358–360, 359f, 360f
- retinal synaptic circuitry development and, 354–357, 355f, 356f
- synaptic activity and, 357–358
- Onchocerca volvulus* infections, 508
- 129/J. *See* 129P3/J strain
- 129P3/J strain
- auditory evoked brainstem response in, 22
- mutation and effect in, 62t
- 129P3/PJ, mutation and effect in, 62t
- pain sensitivity in, 25
- tactile sensitivity in, 24
- 129/ReJ strain, auditory evoked brainstem response in, 22
- 129S1/SvImJ strain
- hearing and visual abilities in, 15t
- 129/S1, olfactory ability in, 22, 23
- pattern discrimination in, 18
- photoreceptor response damage by light and, 575, 577
- visual acuity of, 20
- 129S2/Sv strain, anxiety-related behavior tasks and, 29
- 129/SvEms strain, learning and memory in, 27
- 129/SvEvTac strain
- avoidance learning in, 28
- pattern discrimination in, 18
- 129SvJ. *See* 129X1/SvJ
- 129/SvPasCrl strain, conditioned odor preference in, 28
- 129Sv-ter/C57BL/6 mice, olfactory ability in, 22, 23
- 129X1/SvJ strain
- auditory evoked brainstem response in, 22
- pain sensitivity in, 25
- Open field test, 29
- Operant olfactometer, 22, 23
- Opn⁴^{-/-}* mice, circadian photoentrainment and, 210, 211
- Opsins
- of cones, expression of, 136, 138–139
- development of, 305
- signaling molecules responsible for expression of, 304–306
- Optic chiasm
- regulatory genes in retina and chiasm important for patterning, 396–397
- retinal ganglion cell axon divergence at, 393–396
- crossed projection and, 395–396
- uncrossed projection and, 393–395
- retinal ganglion cell axon guidance toward, 392f, 392–393
- Optic disc
- directed growth of retinal ganglion cell axons toward, 382–384, 383f
- targeting of retinal ganglion cell axons to, 383f, 383–384
- Optic disc astrocyte precursor cells (ODAPs), 390, 390f
- Optic fiber layer (OFL)
- control of initial retinal ganglion cell axon outgrowth polarity in, 381–382, 382f
- retinal ganglion cell axon restriction to, 379–381, 380f
- Optic nerve, 201–204
- astrocytes and astrocyte progenitors in, 390, 390f
- connective tissue in, 203, 203f
- development of, 201–202
- glaucomatous excavation of, prevention by radiation treatment, plate 35
- morphological features of, 201, 202f
- neuronal and glial tissue in, 202–203, 203f
- retinal ganglion cell axon projection through, 391–392, 392f
- vascular supply of, 203–204, 204f
- Optic nerve head, 201, 202f
- Optic neuritis, retinal ganglion cell axon regeneration in, 409
- Optic neuropathy
- glaucomatous, retinal ganglion cell axon regeneration in, 409
- ischemic, retinal ganglion cell axon regeneration in, 409
- traumatic, retinal ganglion cell axon regeneration in, 409, 409f
- Optic vesicle (OV), 267
- Optical imaging, for ocular dominance plasticity assessment, 440f, 440–441, 441f
- Optical interferometry tonometry (OIT), 480
- Optics, of mouse eye, 74
- Optineurin (*OPTN*), primary open-angle glaucoma and, 482
- Optokinetic after-nystagmus (OKAN), velocity storage integrator and, 95f, 95–96
- Optokinetic drum, 20
- Optokinetic nystagmus (OKN), velocity storage integrator and, 95f, 95–96
- Optokinetic reflex (OKR), 88, 91, 91f
- adaptation of, 98f, 98–99, 99f
- measurement of, 112–113, 114f
- Optomotor response, “whole body,” spatial vision and, 81–82
- Optomotor test apparatus, 17f
- Organelles, loss during lens differentiation, 278
- Orienting vestibulo-ocular reflex, 92
- Otolith-ocular reflexes, 91–92, 92f
- Outer nuclear layer (ONL), 635, 636f
- Outer plexiform layer (OPL), 637
- lateral inhibition in, 175
- Oxygen, 559–569
- delivery to retina, 559–561
- choroidal circulation and, 560–561
- retinal circulation and, 559–560
- inhaled
- blocking of vasogenesis by, 563
- killing of photoreceptors by, 562–563, 564f, plate 48
- lack of oxygen supply to outer retina and, 562–563, 563f
- lack of supply to outer retina, 562–568
- acceleration of photoreceptor degeneration by light and, 566
- degeneration of edge of normal retina and, 566–568, 567f
- depletion-induced hyperoxia and, 565–566
- inhaled oxygen and, 562–563, 563f
- reduction in photoreceptor metabolism and, 564–565
- retinal detachment and, 564
- oxygen stress during development and, 568, plate 49
- retinal consumption of, 561–562
- in adults, 561f, 561–562
- developmental onset of, 562
- neuroglobin and, 562
- retinal degeneration and, 568–569
- Oxygen-induced retinopathy (OIR), 285, 553–554
- epithelial cell death and, 293
- mouse model of, 289–294. *See also* Retinopathy, of prematurity (ROP)
- characterization of, 289–291, 291f, 292f
- cytokines and, 292–293
- endothelial cell apoptosis and, 293
- microglia and leukocytes and, 293–294

- Oxygen-induced retinopathy (continued)
retinal flat-mount preparation from,
plate 13
VEGF-A and, 291–292
- P**
- P7 knockout mice, plate 42
P7 wild type mice, plate 42
P21 knockout mice, central retina from,
plate 41
P21 wild type mice, central retina from,
plate 41
p107
retinal development and, 313
rod development and, 316
p130, retinal development and, 313
Pac1r, circadian photoentrainment and,
214
Pain sensitivity, measurement of, 24–25
Paramedian pontine reticular formation
(PPRF), 238
Parasitic infections, 508–509
Pars plicata region, 129
Pathogen-associated molecular patterns
(PAMPs), 519
Pattern electroretinogram (PERG), retinal
ganglion cell activity measurement
by, 119–124, 120f
correlates of visual behaviors and,
120–121, 121f
in human clinical research, 124
limitations of, 124
methods for, 120
in mouse models of glaucoma, 122–124,
123f
in study of central nervous system
plasticity and degeneration, 121–122
Pax6
in cornea and lens development, 699–700
eye field formation and, 301
Notch1 retinal development and, 323–324
Pax6
cataracts and, 493
as eye field transcription factor, 299
Le-Cre mice and, 274
lens development and, 275–277, 276f
retinal ganglion cell development and,
194
retinal development and, 322–323
Pax6 α Cre line, 598
Pax6-Cre;Rb^{Lux1/Lux} mice, rod development in,
314, 315
Pde6b, age-related eye diseases and, 584
Pde6b gene, 14, 63
rd mutation of, 61
rd1 mutation of, 26
Pdeb6b mutations, 650
Pde6b^{rd1} mutation, 271
Pearlman, Alan, 245
PEDF, in gene therapy for retinal
neovascularization, 607, 609
Pentraxins, lateral geniculate nucleus
synaptic remodeling and, 435
Per genes, circadian photoentrainment and,
214, 214f
Pericyte(s), retinal vascularization and, 288,
290–291
Pericyte recruitment, 642
Pericyte-derived angiopoietin-1, retinal
vascularization and, 288
Perlecan, cataracts and, 499–500
Phakinin, cataracts and, 498
Phenotypic variation
alleles as cause of, 649–651
genetic modifiers as cause of, 651–653,
652t
retinal degeneration and, 652–653
Photokeratometry, 76–77, 78f
Photoreceptors, 635, 636f, 637. *See also*
Cone(s); Rod(s)
candidates for light damage quantitative
trait loci and, 577–579, 578t
cell death of, pathways of, 678–679, 679f
Cx36 expression by, plate 5
degeneration of
by light, 566
Pde6b mutations leading to, 650
Rpe65 alleles and, 650–651
Rpgrip1 mutations leading to, 650
degradation of, protection against retinal
neovascularization by, 565
depletion of, raising of oxygen levels in
outer retina by, 565
development of, 304–306
biological network characteristics and
relevance to photoreceptors and,
676–677
critical period in, 568
hierarchy in regulatory networks
underlying photoreceptor
development and, 677–678, 678f
NRL and gene profiling of purified
photoreceptors and, 676, 677f
expression profiling of, degeneration
networks and, 679–680
gap junctions of, 165–166, 166f
killing of, by inhaled oxygen, 562–563,
564f, plate 48
by light damage of, 566
light damage of, 573–579
gene modifier having strong influence
on, 573–575, 576f, 577, 577f
of mouse compared to other mammalian
species, 36
at peripheral margin of retina, stress from
early postnatal life and, plate 49
phagocytosis of outer segments of, 638
promoter transgenes and, 595
reduction in metabolism of, lack of
oxygen supply to outer retina and,
564–565
retinal pigment epithelium relationship
with, 639
targeted ablation to assess role of,
595–596
toxicity of depletion-induced hyperoxia to,
565–566
Photoretinoscopy, infrared, 74–76, 76f, 77
Photosensitivity, circadian, 209
Physical contact, plasticity and, 455f,
455–456
Pigment dispersion syndrome (PDS),
483–485, 484f
Pineal melatonin rhythm, circadian
photoentrainment and, 210
Pitx2, in cornea and lens development, 701
Pitx3, cataracts and, 493–494, 494f
Pitx3, in cornea and lens development, 701
Placental growth factor (PGF), retinal
vascularization and, 286–287
Plasmids, delivery using electroporation. *See*
Electroporation
Plasminogen activator inhibitor-1 (PAI-1),
diabetes and, 550–551
Plasticity
environmental enrichment and. *See* Visual
cortical plasticity
in lateral geniculate nucleus, mouse
compared to other species and,
432–433
ocular dominance. *See* Ocular dominance
(OD) plasticity
reticulogeniculate synapses remodeling
and, 431–432
Platelet-derived growth factor-A (PDGF-A),
retinal vascularization and, 287
Platelet-derived growth factor-B (PDGF-B)
diabetes and, 551
retinal vascularization and, 288
Postrotatory nystagmus (PRN), 94
Posttranslational modifications, of proteins,
715
Potassium currents, in dorsolateral geniculate
nucleus, 220–221
POU homeodomain transcription factors, in
cornea and lens development, 701
POU4f1, retinal ganglion cell development
and, 194
Pou4f2
expression in retinogenesis, plate 16
genes regulated by, 327–328
POU4f2, retinal ganglion cell development
and, 194
POU4f3, retinal ganglion cell development
and, 194
PPT1, 612
P/Q mutants, 101
Presumptive lens ectoderm (PLE), 267
Primary congenital glaucoma (PCG), 483
Primary open-angle glaucoma (POAG)
models of, 489
mouse model of, 481–482
Prior experience, enhancement of ocular
dominance plasticity by, 445f,
445–446, 446f
Promoter transgenes, and photoreceptors,
595
Prostaglandin analogues, for intraocular
hypertension and glaucoma, 644
Protein(s). *See also specific proteins*
posttranslational modifications of, 715
proteome-wide identification of species of,
715
Rb family of, retinal development and,
311–319
intrinsic genetic compensation and
redundancy and, 312f, 312–313

Protein(s) (continued)
 rod development and, 216f, 313–317, 315f
 species-specific differences in Rb family compensation and, 313
 synaptogenesis defects in Rb-deficient retinas and, 317–318, 318f

Protein-bound carbohydrates, cataracts and, 499–500

Proteomics
 definition of, 711
 glaucoma therapy and, 488
 of lens, 711–718
 of visual cycle, 727–729
 of interacting components, 727–729

Prox1, lens fiber differentiation and, 278

Prox1, in cornea and lens development, 700–701

Prph2^{Rd2/Rd2} mouse, gene replacement therapy for, for retinal degeneration in, 610–611

prRd1c^{-/-} mice, 723

Pseudomonas aeruginosa infections, 506–507, 508

Ptf1a, *Math5* repression in retinal progenitor cells and, 326–327

Purkinje cell degeneration mice, 101

Q

Quantitative trait genes (QTGs), for light damage, 577–579, 578t

Quantitative trait locus (QTL) analysis, 63, 64f, 65f

Quantitative trait locus (QTL) mapping, 668–669, 670

R

Radial arm maze, 26–27

Radial glia, midline, in retinal ganglion cell axon projection pathway, 390–391

Rafferty, Nancy, 270

RALDH3 band, medial, anatomical locations of, plate 20

Ramón y Cajal, S., 635

Rapid eye movements, saccade-like, 233
 electrically induced, in mice, 235–238, 237f
 measurement of, 233–234, 234f
 spontaneous, in mice, 234f, 234–235, 236f

Rb family of proteins, retinal development and, 311–319
 intrinsic genetic compensation and redundancy and, 312f, 312–313
 rod development and, 216f, 313–317, 315f
 species-specific differences in Rb family compensation and, 313
 synaptogenesis defects in Rb-deficient retinas and, 317–318, 318f

RBP receptor, in visual cycle, 725

RDH5 gene, 725

RDH12 mutations, 723

Receptive fields (RFs), of dorsolateral geniculate nucleus cells, 221–224, 223f

Refractive errors
 induction of, by frosted diffusers or spectacle lenses, 82–83
 in knockout mouse models, 83

Regeneration, of retinal ganglion cell axons.
See Retinal ganglion cells (RGCs), axon growth and regeneration of

Regulatory networks
 degeneration and, expression profiling of photoreceptors from *rd* mice and, 679–680
 model for retinal ganglion cell development, plate 15
 photoreceptors and, 676–677
 underlying photoreceptor development, hierarchy in, 677–678, 678f

Reinforcement-based tasks, for measuring visual perception, 109–111, 111f–113f

Reticulogeniculate synapses. *See* Lateral geniculate nucleus (LGN), synaptic remodeling in

Retina
 cell types in, 635, 636f, 637
 developing, plate 14
 electroporation and. *See* Electroporation gap junctions in. *See* Gap junctions inducible RNAi in, plate 62
 layers of, plate 64
 lineage tracing in, using cell type-specific promoters, plate 60
 mature, plate 14
 mosaic architecture of, 147–153
 cholinergic amacrine cells and, 150–151, 151f
 development of, 147–148, 148f
 dopaminergic amacrine cells and, 151–153
 horizontal cells and, 148–150, 149f, 150f
 of mouse compared to other mammalian species, 35–39
 multicolor labeling of, using cell type-specific promoters, plate 59
 normal, degeneration of edge of, lack of oxygen supply to outer retina and, 566–568, 567f
 outer, lack of oxygen supply to, 562–568
 acceleration of photoreceptor degeneration by light and, 566
 degeneration of edge of normal retina and, 566–568, 567f
 depletion-induced hyperoxia and, 565–566
 inhaled oxygen and, 562–563, 563f
 reduction in photoreceptor metabolism and, 564–565
 retinal detachment and, 564
 outer, raising of oxygen levels in, by light, 565
 oxygen consumption of, 561–562
 in adults, 561f, 561–562
 developmental onset of, 562
 neuroglobin and, 562
 oxygen delivery to, 559–561
 retinal circulation and, 559–560
 physiology of, in norrin knockout mice, 530
 retinal ganglion cell axon exit from, 391
 vascular development of, in norrin knockout mice, 530–531, 531f, 532f
 whole mount, confocal image of, plate 4

Retinal antigen, experimental autoimmune uveitis induced by, 515, 516f, 517f

Retinal circulation, oxygen delivery to retina and, 559–560

Retinal degeneration, 675–680
 age-related, in human and mouse eyes, 582, 584–588
 expression profiling of photoreceptors from *rd* mice and, 679–680
 expression profiling using microarrays and, 575–576
 gene replacement therapy for, 610–611
 gene therapy for, 675
 genetic modification of, 652–653
 light-induced, 16
 mouse strains with, 16
 mouse models of, 678–679, 679f
 synaptic reorganization due to, 317–318

Retinal detachment
 lack of oxygen supply to outer retina and, 564
 retinopathy of, oxygen to relieve, 564

Retinal G protein-coupled receptor (RGR), in visual cycle, 724–725

Retinal ganglion cells (RGCs)
 activation of, *Math5* and, 325
 axon growth and regeneration of, 401–410
 area of action of extracellular signals and, 402–403, 403f
 control of neuronal responsiveness to trophic peptides and, 404f, 404–405
 dendrite growth ability and, 406–407, 407f
 developmental regulation of intrinsic growth and, 405–406, 406f
 extracellular signals inducing growth and, 401–402, 402t
 glaucoma and, 486–487, 487f
 intrinsic and extrinsic control of regeneration and, 409–410
 mechanism of axon induction by extracellular signals and, 403–404
 molecular changes underlying developmental loss in rapid axon growth ability and, 407–408
 need for specific extrinsic signals for growth and, 401, 402f
 regeneration in mature visual system, 408–409
 regulation of, 409–410
 study of, 409, 409f
 study of regeneration and, 409, 409f
 axon outgrowth and pathfinding and, 379–386, 380f
 control of initial polarity of outgrowth within optic fiber layer and, 381–382, 382f

- Retinal ganglion cells (continued)
- directed growth toward optic disc, 382–383, 383f
 - dorsal-ventral differences in
 - mechanisms regulating, 385–386
 - growth cones and guidance cues and, 379, plate 21
 - regulation of, 328
 - restriction of axons to optic fiber layer and, 379–381, 380f
 - targeting to optic disc and exit from eye, 383f, 383–385
 - axonal exit from retina and, 391
 - cell death of, 333, 334
 - in glaucoma, 479, 481, 485–487, 487f, plate 33, plate 34
 - matching sizes of interconnected neuronal populations and, 335, 335f
 - molecules involved in signaling, regulating, and executing, 337, 338
 - neurotrophic hypothesis of, 336
 - classes of, distinguishing, 189–190, 190f, 191f, 192
 - competence of, *Math5* and, 324
 - crush injury of, plate 23
 - dendrites of, growth ability of, axon
 - growth ability and, 406–407, 407f
 - development of, 321–330, 322f
 - developmental regulation of retinal ganglion cell subtypes and, 329
 - early regulatory events in, 322–324
 - gene regulatory network for, 321–322, 323f
 - Math5* and, 324–325
 - regulation of *Math5* expression and, 325–327
 - regulation of retinal ganglion cell differentiation downstream of *Math5* and, 327–329
 - in vitro generation of retinal ganglion cells from embryonic stem cells and, 329–330
 - developmental timing and, 261
 - differentiation of, downstream of *Math5*, regulation of, 327–329
 - direction-selective
 - calcium imaging of responses of, 598
 - genetic tagging to study responses of, 598
 - functional properties of, 192
 - development of, 194–197
 - generation and differentiation of, 193–194
 - generation from embryonic stem cells, in vitro, 329–330
 - genetic approaches for study of, 599
 - intrinsically photosensitive, 192, 211–212
 - morphology, ontogeny, and functional diversity of, 211–212, 212f
 - phototransduction mechanism and, 213–214
 - target brain regions innervated by, 212f, 212–213
 - melanopsin-expressing, circadian photentrainment and, 210–211
 - molecular markers for, 192–193
 - morphological properties of, plate 6
 - development of, 194, 195f, 196f
 - of mouse compared to other mammalian species, 35, 37–38
 - ON and OFF pathway segregation and, 353–354, 355–360
 - mechanisms of, 358–360, 359f, 360f
 - retinal synaptic circuitry development and, 354–357, 355f, 356f
 - synaptic activity and, 357–358
 - synaptic circuitry development and, 355f, 355–357, 356f
 - ON-center, alteration of visually and electrically evoked responses of, by GABA_CR-mediated feedback inhibition, 183–184, 184f
 - pattern electroretinogram measurement of function of, 119–124, 120f
 - correlates of visual behaviors and, 120–121, 121f
 - in human clinical research, 124
 - limitations of, 124
 - methods for, 120
 - in mouse models of glaucoma, 122–124, 123f
 - in study of central nervous system plasticity and degeneration, 121–122
 - phenotypes of, complex, altered outer retinal neurotransmission resulting in, 179
 - “pioneer axons” of, 389
 - projections of, 192, plate 6
 - albinism and, 397
 - axon divergence at chiasm and, 393–396
 - early development of, 389, 390f
 - glia in projection pathway and, 390–391
 - guidance cues and, 391f, 391–393, plate 21
 - late phase of development of, 390, 390f
 - middle phase of development of, 389–390, 390f
 - new approaches for study of, 397, 398f
 - regulatory genes in retina and chiasm important for chiasm patterning and, 396–397
 - techniques for studying, plate 22
 - retinal waves and. *See* Retinal waves
 - spontaneous burst activities of. *See* Retinal waves
 - subtypes of, developmental regulation of, 329
 - survival after lesion, 122, 123f
 - YFP expression, dendritic ramification patterns of, plate 19
 - Retinal infections, mouse models of, 509
 - Retinal neovascularization
 - Bcl-2 and, 293
 - gene therapy for, 607, 609–610
 - limitation by laser burns, 565
 - protection against, by degradation of photoreceptors, 565
 - Retinal network, of mouse compared to other mammalian species, 36f, 36–37
 - Retinal pigment epithelium (RPE), 637–639, 639f, plate 64
 - function of, 638
 - gene expression in
 - correlation of retinal pigment epithelium gene expression and retinal vascularization and, 692–693
 - isolation of retinal pigment epithelium and, 688, 689f, 690f, 690–691
 - lipofuscin of, 539–544, 540f, 638
 - autofluorescence of, plate 44
 - inhibiting formation of fluorophores and, targeting visual cycle for, 543f, 543–544
 - Leu450Met variant in murine Rpe65 associated with, 542–543, 543f
 - Rpe65^{-/-} mice and, 539–540, 540f
 - Stargardt macular degeneration and *Abca4/Abcr* null mutant mice and, 540–542, 541f
 - relationship with photoreceptors, 639
 - visual cycle and, 721–722
 - Retinal progenitor cells (RPCs)
 - differentiation of, 302
 - eye field transcription factor expression in, 299, 302–303
 - Math5* activation in, 325
 - Math5* repression in, 326–327
 - proliferation of
 - control by retinal ganglion cell-secreted signaling molecules, 328–329
 - regulation of, 311
 - Retinal projections, ipsilateral and contralateral, plate 1
 - Retinal synaptic transmission, 175–184, 176f
 - control of synaptic output of bipolar cells by GABA_CR-mediated inhibition and, 182–183
 - evoked response alteration of ON-center retinal ganglion cells by GABA_CR-mediated inhibition and, 183–184, 184f
 - in outer retina, 175–179
 - altered, complex retinal ganglion cell phenotypes resulting from, 179
 - postsynaptic mutants and, 177t, 178–179, 179f
 - presynaptic mutants and, 177t, 177–178
 - retinal ganglion cell responses in mutants with outer plexiform layer presynaptic defects and, 179–181, 180f
 - retinal ganglion cell responses in mutants with postsynaptic defects in depolarizing bipolar cell signaling and, 181
 - Retinal vasculature, plate 45
 - degenerate capillaries in, plate 46
 - development of, 285–289, 286f, 289f
 - gene expression in
 - correlation of retinal pigment epithelium gene expression and retinal vascularization and, 692–693

- Retinal vasculature (continued)
 isolation of retinal vasculature and subsequent gene expression studies and, 688, 689f, 691–692
 leukocyte adherence in retinal microvasculature of diabetic mouse and, plate 47
- Retinal waves, 343–348
 cellular mechanisms underlying, retinal development and, 343–344, 344f
 circuits generating, functional stages of, plate 17
 gap junctions and, 346–347
 measurement techniques for, 343
 mediation of, 357
 stage I, properties of, 347, plate 18
 stage II
 mechanisms of, 345f, 345–346
 properties of, plate 18
 spatiotemporal properties of, 344–345, 345f
 stage III, properties of, 347
 visual circuit development and, 348, 349f
- Retinaldehyde, 364
- Retinaldehyde dehydrogenases (RALDHs), 364
 RALDH2, 367, 367f
 RALDH3, 367, 368f
 colocalization with markers for neuronal plasticity, 368, 369f
 maturation patterns in postnatal cortex defined by, 369–370, 370f
 relationship between neurotrophin-3 and, 368–369, 369f
 retinoic acid colocalization with sites of expression of, 365f, 365–366
- Retinitis, viral, 509
- Retinoblastoma
 human susceptibility to, 311, 313
 species-specific differences in susceptibility to, 313
- Retinofugal projections, of mouse compared to other mammalian species, 39t, 39–40, 40f, 41f
- Retinogenesis, early regulatory events in, 322–324
- Retinogeniculate pathway. *See also* Lateral geniculate nucleus (LGN)
 axon segregation in, in developing mouse, plate 24
 development of, 415–426, 425f
 functional composition of developing pathway and, 419–420, 421f, 422
 mechanisms underlying remodeling of connections and, 424
 structural composition of developing pathway and, 418–419
- Retinohypothalamic tract (RHT), circadian photoentrainment and, 209–210
- Retinoic acid (RA), 363–374
 actions in brain, 364–365
 data bank searches and, 370–372
 Allen Brain Atlas, 370–371, 371f
 Brain Gene Expression Map, 370
 evaluation of, 372
 dorsal telencephalon function and, 366–367
 dorsal visual stream and, 373f, 373–374
 photoreceptor development and, 304, 305
 RALDH2 and, 367, 367f
 RALDH3 and, 367, 368f
 colocalization with markers for neuronal plasticity, 368, 369f
 maturation patterns in postnatal cortex defined by, 369–370, 370f
 relationship between neurotrophin-3 and, 368–369, 369f
 reporter mice and, 365f, 365–366
 retinoid system and, 364
- Retinoid flow in visual cycle, in visual cycle, 726–727
- 11-*cis*-Retinol dehydrogenase, in visual cycle, 725
- Retinol-binding protein, in visual cycle, 725
- Retinopathy
 of detachment, oxygen to relieve, 564
 diabetic. *See* Diabetic retinopathy
 oxygen-induced, 553–554
 of prematurity (ROP), 285–294, 642
 mouse model for study of, 285, 289
 scoring system for, 291
- Retinopathy scoring system, 291
- Retinorecipient nuclei, of mouse compared to other mammalian species, 40–45
- Retinoscopy, streak, 75
- RF/J strain, hearing and visual abilities in, 16
- Rgr*^{-/-} mice, 724, 725
- Rhodopsin gene, 63
- Rhodopsin gene mutations, 651
- RIIS/J strain, tactile sensitivity in, 24
- Rlbp*^{-/-} mice, 726
- RNAi, inducible, in retina, plate 62
- Rod(s). *See also* Photoreceptors
 bipolar cells of, ON and OFF pathway segregation and, 354
 development of, Rb and, 313–317, 315f, 316f
 dysfunction of, cone damage due to, 566
 gap junctions of, 167
 GFP expression in, plate 63
 of mouse compared to other mammalian species, 36
 scaling of, 263
 spatial vision and, 81–82
- Rod monochromatism, gene replacement therapy for, 612–613
- Rod pathways, proximal, gap junctions in, 167–169, 168f
- Rod visual cycle. *See* Visual cycle, rod
- Roscoe B. Jackson Memorial Laboratory, 13
- Rpe65, Leu450Met variant in, reduced levels of retinal pigment epithelial lipofuscin associated with, 542–543, 543f
- Rpe65*, photoreceptor response to light and, 574–575
- RPE65 alleles, 638–639, 639f
- Rpe65* alleles, retinal responses to light exposure and, 650–651
- Rpe65* knockout mice, as model for Leber congenital amaurosis, 611–612
- Rpe65*^{-/-} mice, photosensitivity in, 214
- Rpe65^{-/-} mice, retinal pigment epithelium lipofuscin in, 539–540, 540f
- Rpgrip* knockout mice, as model for Leber congenital amaurosis, 612
- Rpgrip 1* mutations, 650
- RPR65, 637
 isomerohydrolase reaction and, 723–724
- Rupture of lens cataract, 501
- Rx*, as eye field transcription factor, 299–300
- Rx-Cre* transgenic mice, 274
- RXR- τ , opsins and, 305
- Rx/rax* homeobox transcription factor, 269

S

- Saccade(s), 87, 88, 99
- Saccade-like rapid eye movements (SLREMs), 233
 electrically induced, in mice, 235–238, 237f
 measurement of, 233–234, 234f
 spontaneous, in mice, 234f, 234–235, 236f
- Saccadic eye movements, 233–242
 study methods for, 233
 superior colliculus and, 233. *See also* Superior colliculus (SC)
- SB strain, mutation and effect in, 62t
- Scaling, of eye and cortex, 263–264
- Schematic eye modeling, 73–74, 74f
- Schlemm's canal
 aqueous humor outflow and, 131
 inner wall cells of, 132, 132f
- Scotopic signal transmission, of mouse compared to other mammalian species, 36f, 36–37
- Scotopic threshold response (STR), pattern electroretinography and, 124
- Second messengers, retinal ganglion cell axon growth ability and, 408
- Self-complementary AAV vectors (scAAV), 613–614
- Senescence-accelerated mouse (SAM), 500
- Senile cataracts, mouse models for, 500
- Sequential model of evolution, 6–7, 7f
- Serial analysis of gene expression (SAGE), 662, 663, 687
- Severe combined immunodeficiency (SCID), 506
- Shh*, control of retinal progenitor cell proliferation by, 328
- SHIRPA test battery, 30
- Shrew mice, 3–5, 8
- Single-cell recordings, cones and, 139, 140f–142f
- Single-unit recordings, for ocular dominance plasticity assessment, 439
- Sinusoidal stimuli, optokinetic reflex gain in response to, 91
- Sip 1*, lens development and, 277
- Sip1*, in cornea and lens development, 701
- Site-specific recombination, Cre-lox recombinase system for study of, 599–600
- Six3, in cornea and lens development, 700
- Six homeodomain genes, as eye field transcription factors, 300

- SJL/J strain
 anxiety-related behavior tasks and, 29
 conditioned taste aversion in, 29
 cued and contextual fear conditioning in, 27
 hearing and visual abilities in, 15t, 16
 mutation and effect in, 62t
 pattern discrimination in, 18
 visual acuity of, 20
- SKH2/J strain, auditory evoked brainstem response in, 22
- Slit1*, retinal ganglion cell axon guidance through visual pathway and, 392f, 392–393
- Slit2*, retinal ganglion cell axon guidance toward optic chiasm and, 392f, 392–393
- Slit signaling, control of initial retinal ganglion cell axon outgrowth polarity in, 381–382, 382f
- Small eye artifact, 74
- Smithies, Oliver, 35
- SM/J strain
 pattern discrimination in, 18
 tactile sensitivity in, 24
 taste ability in, 23
 visual acuity of, 20
- Smooth pursuit movements, 87, 88
- Snell, George D., 13
- Sodium currents, in dorsolateral geniculate nucleus, 220, 220f
- Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), in proteomics, 713–714
- Sonic hedgehog. *See also Shh*
 directed growth of retinal ganglion cell axons toward optic disc and, 383
 eye field formation and, 301
 optic nerve development and, 201
- S-opsin, cone, expression of, 136, 138–139
- Sorsby's fundus dystrophy, gene therapy for, 609–610
- Sox*, cataracts and, 494
- Sox1*, lens fiber differentiation and, 278
- Sox1*, in cornea and lens development, 701
- Sox2*
 in cornea and lens development, 701
 lens development and, 276
- Spacing rule, in horizontal cell mosaic, 148–150, 149f, 150f
- Spatial acuity, primary visual cortex and, 51–52
- Spatial frequency (SF) threshold, of optokinetic reflex, measurement of, 113–115, 114f, 115f
- Spatial information, retinogeniculate inputs and, 221–223, 222f–224f
- Spatial regulation, of gene expression, using cell type-specific promoters, plate 58
- Spatial resolution
 of mouse compared to other mammalian species, 38–39
 in mouse eye, 73
- Spatial vision
 illuminances and, 81, 81f
 rods and cones and, 81–82
- Spectacle lenses, refractive errors induced by, 82
- Spemann, Hans, 268
- Spiny mice, 3–4, 5, 8
- Sp1/Krüppel-like transcription factors, in cornea and lens development, 702
- Spontaneous activity, developmental, postnatal retinal ganglion cell development and, 121–122, 122f
- SPRET/Eij strain
 hearing and visual abilities in, 15t
 pattern discrimination in, 18
 visual acuity of, 20
- Staggerer mutant mice, olfactory ability in, 22, 23
- Staphylococcus aureus* infections, 507–508
- Starburst amacrine cells (SACs)
 retinal waves and, 346
 study approaches for, 598
- Stargardt disease, 582, 723
 in *Abca4/Abcr* null mutant mice, 540–542, 541f
- Stimulation. *See also* Environmental enrichment
 early-life, neuronal and behavioral development and, 450–451
 electrical, retinal ganglion cell axon growth and, 404–405
 tactile, plasticity and, 455, 456
- Stimulus-selective response potentiation (SRP), 471–472, 472f, 473
- Strain background, 65
- Stratification patterns, Cre-lox recombinase system for study of, 601
- Stratum album intermediale (SAI), 235
- Stratum album profundum (SAP), 235
- Stratum griseum intermediale (SGI), 235
 burst generation in, 240–241, 241f
 cholinergic innervation of, 242
- Stratum griseum profundum (SGP), 235
- Stratum griseum superficiale (SGS), 43, 235
- Stratum opticum (SO), 43, 235
- Stratum zonale (SZ), 235
- Streak infrared, 75
- Streak retinoscopy, 75
- Streptozotocin, diabetes induced by, 548–549, 549f
- Strong, Leonell C., 13
- Sugar-induced cataracts, in mouse, 499
- Sulik, Kathleen, 270
- Superior colliculus (SC), 233
 electrically induced saccade-like rapid eye movements and, 235–238, 237f
 lateral geniculate nucleus synaptic remodeling and, 433–434
 layers of, 235
 local circuits of, 238–242
 burst generation mechanism and, 239–241, 241f
 cellular properties of, 238, 238f
 GABAergic, 239
 interlaminar connections and, 239, 240f
 neuromodulator actions and, 241–242
 retinal projections to, 42f, 42–44, 43f
- Superoxide dismutase, diabetic retinopathy and, 553
- Suprachiasmatic nucleus (SCN)
 circadian photoentrainment and, 209–210, 211, 212f, 212–213
 retinal projections to, 40, 41, 212f, 212–213
- SvEvTac. *See* 129/SvEvTac strain
- SWR/J strain, hearing and visual abilities in, 16
- Synaptic circuitry, retinal, development of, ON and OFF pathway segregation and, 354–357, 355f, 356f
- Synaptic remodeling, 429–435
 description of, 429
 in lateral geniculate nucleus, 430f, 430–431, 431f
 activity and, 431–432
 comparison with remodeling in other regions of visual system, 433–434
 genes involved in, 434–435
 plasticity in lateral geniculate nucleus and, 432–433
 lateral geniculate nucleus synapses and, 429–430
- Synaptic transmission, retinal. *See* Retinal synaptic transmission
- Synaptogenesis, defects in *Rb*-deficient retinas, 317–318, 318f

T

T cells

- antigen-specific
 experimental autoimmune uveitis induced by adoptive transfer of, 515
 migration to eye, 521
 defects in selection of repertoire of, susceptibility to experimental autoimmune uveitis and, 518
 deficient peripheral tolerance and, susceptibility to experimental autoimmune uveitis and, 518–519
Pseudomonas aeruginosa infections and, 507
- Tactile sensitivity, measurement, 24
- Tactile stimulation, plasticity and, 455, 456
- Tail flick test, 24
- TALE homeobox proteins, eye field transcription factor regulation by, 301
- Targeted ablation, to assess role of photoreceptors, 595–596
- Targeted gene manipulations, 594–595, 595f
- Targeted mutagenesis, 63, 65–66
- Taste ability, measurement of, 23–24
- Taste aversion, conditioned, 28–29
- Tau-lacZ reporter, for study of retinal ganglion cells, 599
- Taurine, photoreceptor development and, 304, 305
- Tcm* mutant, 501

- Telencephalon, dorsal, retinoic acid and, 366–367
- Temporal information, retinogeniculate inputs and, 223–225
- Temporal resolution, primary visual cortex and, 51–52
- Tetrodotoxin (TTX), lateral geniculate nucleus synaptic remodeling and, 434
- Th1, experimental autoimmune uveitis and, 520
- Th17, experimental autoimmune uveitis and, 520
- Thalamocortical relay cells (TCs)
 - calcium current of, 220
 - hyperpolarization-activated currents of, 221
 - intrinsic conductances of, modulation of, 226–227
 - potassium current of, 220–221
- Thalamus, dorsal and ventral, visual cortex connections with, 46
- Thanatins, cell death and, 337
- Thermal nociception, measurement of, 24–25
- Thy-1
 - fluorescent reporters under control of, 598
 - as retinal ganglion cell marker, 193
- Thy-1-GFP-H line, for study of retinal ganglion cells, 599
- Thymidine birth dating analysis, in retina, 302
- Thyroid hormone receptor- β_2 (*TR β 2*), opsins and, 305
- Tilt, static, mouse response to, 92f, 92–93
- Tilt vestibulo-ocular reflex (titVOR), 92
- Tilted mice, 101
- TIMP3, gene therapy for Sorsby's fundus dystrophy using, 610
- Tissue inhibitor of matrix metalloproteinase-1, herpes simplex virus infection and, 506
- Toll-like receptors (TLRs)
 - autoimmunity triggered by, 519–520
 - infections and, 508
- Tonometry, 480
- Tono-Pen tonometer, 480
- Toxoplasma gondii* infections, 509
- Trabecular meshwork (TM), 131f, 131–132, 132f
 - in pigment dispersion syndrome, 484
 - in primary open-angle glaucoma, 484
- Transcallosal cells, binocularity and, 50–51
- Transcription factors. *See also specific factors*
 - cell death and, 338
 - in cornea and lens development, 699f, 699–703, plate 36, plate 66
 - homeobox, 699–701
 - non-homeobox, 702–703
 - photoreceptor development and, 304–305
 - retinal ganglion cell development and, 194
- Transforming growth factor β (TGF- β)
 - cell death and, 336
 - retinal vascularization and, 290–291
- Transforming growth factor β_1 (TGF- β_1), retinal vascularization and, 288
- Transgene insertion, 593–594, 594f
- Transgenic mice, 14–15. *See also specific transgenic mice*
 - in gene expression analysis, 692
 - for lens research, 272–273
 - location of transgene, 65–66
 - study of amacrine cells using, 597–598
 - study of role of gap junctions in bipolar cells using, 596–597
 - temporal control of gene expression in, Cre recombinases for, 626, 627f, plate 57
 - uses of, 65
- Translational vestibulo-ocular reflex (transVOR), 92
- Traumatic optic neuropathy, retinal ganglion cell axon regeneration in, 409, 409f
- T α 1–3RT τ TG mice, olfactory ability in, 22, 23
- Two-bottle test, of taste ability, 23–24
- Two-dimensional electrophoresis, in proteomics, 714–715
- Tyrosine hydroxylase (TH), primary congenital glaucoma and, 483
- Tyrl^h*, pigmentary glaucoma and, 483
- ## U
- Unmyelinated region, of optic nerve, 201, 202f
- Usher's syndrome, type 1b, 584
- Uveitis, 513–523
 - endotoxin-induced, 513–515, 514f
 - experimental autoimmune uveitis, pathogenesis of, critical checkpoints in, plate 40
 - experimental autoimmune uveoretinitis, 515–517
 - associated with anti-tumor response to melanoma antigen, 517
 - histology of, plate 39
 - in human lymphocyte antigen transgenic mice, 516
 - induced by active immunization with retinal antigen, 515, 516t, 517f
 - induced by adoptive transfer of antigen-specific T cells, 515
 - induced by injection of antigen-pulsed dendritic cells, 516
 - in mice expressing a transgenic target antigen in the retina, 515–516
 - spontaneous, 516–517
 - immunotherapeutic approaches for, 522–523
 - infectious. *See* Infectious eye diseases
 - mechanisms involved in, 517–522
 - antigen presentation to lymphocytes and, 519
 - deficient peripheral tolerance as, 518–519
 - effector cell migration, infiltration, and inflammatory cell recruitment as, 521
 - innate immune signals and, 519–520
 - natural resolution mechanisms as, 521–522
 - pathogenic effectors and, 520
 - T cell repertoire selection and, 518
- Uveoscleral outflow pathways, 132–133
- ## V
- Vacuolated lens* mutant, 500
- V-amacrine cells, 597
- Vascular cell types, 639–643, 641f, 643f
- Vascular endothelial growth factor (VEGF)
 - gene therapy for retinal neovascularization and, 609
 - herpes simplex virus infection and, 506
 - overexpression of, diabetic retinopathy and, 554
- Vascular endothelial growth factor-A (VEGF-A)
 - in angiogenesis, 640–641
 - oxygen-induced retinopathy and, 290, 291–292
 - retinal vascularization and, 286, 287
- Vascular patterning, 642
- Vascularization, 640, 641f
- Vasculogenesis, 285, 286
- Vasogenesis, blocking of, by inhaled oxygen, 563
- Vax1*, optic nerve development and, 201
- Vax1/2*, chiasm patterning and, 396
- Vegf*, control of retinal progenitor cell proliferation by, 328, 329
- Velocity storage integrator, 94–96, 95f
- Ventrolateral geniculate nucleus (vLGN), retinal projections to, 40, 41
- Vergence movements, 87, 88
- Vestibular compensation, 99
- Vestibulo-ocular reflex (VOR)
 - angular, 88–91, 89f, 90f
 - gain and response axis of, adaptation of, 96–98, 97t
 - linear, 88
 - tile (orienting), 92
 - translational, 92
 - visual, 89f, 89–90
- Vibrissae sensitivity, measurement, 24
- Vimentin, cataracts and, 498
- Viral retinitis, 509
- Virtual optokinetic reflex system, 112–113, 114f
- Virtual optokinetic system, 20
- Vision
 - lack of, environmental enrichment and, 453–455, 454f
 - in tasks evaluating higher order cognitive functions, 25
- Visual ability
 - measures of
 - of brightness/visual detection, 16, 17f, 18
 - gross, 16
 - of pattern discrimination, 17f, 18, 19f
 - of visual acuity, 18, 20, 21f
 - in mice, 15t, 16–20
- Visual acuity
 - of mouse compared to other mammalian species, 35
 - operational definition of, 108
 - of small vertebrate eyes, 73

- Visual behavior, correlates of ocular dominance plasticity and, 447
- Visual circuits, development of, retinal waves and, 348, 349f
- Visual cortex, 245–252
- binocular
 - mapping ocular dominance in, plate 26
 - retinotopic mapping of, plate 25
 - callosal connections of, 46–47, 47f
 - connections of, 248–251
 - areal hierarchy of, 251, 251f
 - consolidation of, environmental enrichment and, plate 29
 - between different cortical areas, 249, 250f, 251
 - with dorsal thalamus, 46
 - subcortical inputs and, 248
 - within V1, 248–249
 - with ventral thalamus and mesencephalon, 46
 - Vi, topographic maps of, plate 8
 - corticotectal cells of, physiology of, 47–48
 - cytoarchitectonic fields of, 245, 246f
 - extrastriate, in mouse compared with other mammalian species, 51–52, 52f
 - extrastriate lateromedial area intracortical connections in, plate 9, plate 10
 - interareal feedforward and feedback connections in, laminar organization of, plate 11
 - intrinsic associational corticocortical connections of, 46
 - long-range associational corticocortical connections of, 46
 - maps of, plate 7
 - of mouse compared to other mammalian species, 45–52
 - anatomy and, 45f, 45–47
 - binocularity and, 49–51, 50f
 - physiology and, 47–59, 48t
 - spatial acuity and temporal resolution and, 51–52
 - nonoriented cells of, physiology of, 47
 - orientation selectivity of, 48–49
 - relationship between cytoarchitectonic areas and topographic maps of, 248
 - topographically defined areas of, 246f, 246–248, 247f
 - visuotopic organization of, 45–46
- Visual cortical plasticity
- environmental enrichment and, 449–459
 - early-life stimulation effects on neuronal and behavioral development and, 450–451
 - neural consequences of environmental enrichment and, 450
 - visual system development and, 451–459, 452f, 454f, 455f, 457f, 459f
- experience-dependent, 465–473
- adult ocular dominance plasticity and, 472–473, 474f
 - mechanisms of ocular dominance shift in mice and, 468–471
 - monocular deprivation in juvenile mice and, 468, 469f, 470f
 - stimulus-selective response potentiation and, 471–472, 472f
 - visually evoked potential recording technique and, 466, 467f, 468
- Visual cycle, 721–729
- cone, 727, 728f, plate 69
 - inhibition of formation of retinal pigment epithelial lipofuscin fluorophores and, 543f, 543–544
 - proteomic analysis of, 727–729
 - of interacting components, 727–729
 - retinoid, 637
 - rod, genetic analysis of, 721–727, 722f, plate 68
 - all-*trans*-retinol dehydrogenase and, 722–723
 - ATP-binding cassette A4 and, 723
 - cellular retinaldehyde-binding protein and, 726
 - cellular retinol-binding protein type 1 and, 725
 - 11-*cis*-retinol dehydrogenase and, 725
 - interphotoreceptor retinoid-binding protein and, 726
 - isomerohydrolase and, 723–724
 - lecithin:retinol acyltransferase and, 723
 - retinal G protein-coupled receptor and, 724–725
 - retinoid flow in visual cycle and, 726–727
 - retinol-binding protein and RBP receptor and, 725
- Visual detection, measurement of, 16, 17f, 18
- Visual evoked potentials (VEPs)
- for ocular dominance plasticity assessment, 439–440, plate 31
 - pattern electroretinographic measurement of, 120–121, 121f
 - recording of, for assessing visual cortical plasticity, 466, 467f, 468
- Visual field, of mouse compared to other mammalian species, 39t, 39–40, 40f, 41f
- Visual function, measuring gains and losses of, behavioral methods for, 116, 116f
- Visual pathways, organization of, plate 1
- Visual phenotypes, screening of, behavioral methods for, 115–116
- Visual stimulation, ON and OFF pathway segregation and, 357–358
- Visual system
- development of
 - acceleration by environmental enrichment, plate 28
 - consolidation of visual cortical connections and, plate 29
 - environmental enrichment and, 451–459, 452f, 454f, 455f, 457f, 459f, plate 29, plate 30
 - special features in mouse affecting research, 66–67
 - Visual thalamus. *See* Lateral geniculate nucleus (LGN)
 - Visual vestibulo-ocular reflex (VVOR), 89f, 89–90
 - Visual water box, 16, 17f, 18, 20
 - Visual water task, for measuring visual perception, 110–111, 111f, 112f
 - Visual-somatosensory interaction, 24
 - Vitamin A. *See also* Retinoic acid (RA)
 - deficiency of, 364
 - excess of, 364
 - role in vision, 363
 - uptake from RBP, 725
 - Vogt-Koyanagi-Harada disease, 516
 - von Frey filament test, 24
 - Vpac2r, circadian photoentrainment and, 214
- ## W
- Water T-maze, modified, 16, 17f
- Whole-cell voltage-clamp recordings, for retinal wave measurement, 343
- Williams syndrome, visual cortical functions in, 245
- Wnt signaling, eye field transcription factor regulation by, 300–301
- Wolbachia*, 508
- ## X
- X-linked juvenile retinoschisis (XLRS), gene replacement therapy for, 611
- X-linked recessive familial exudative vitreoretinopathy (XLEVR), 528
- ## Y
- Yamamoto, Yuhiro, 270
- Yerkes apparatus, 16, 17f
- ## Z
- Zernike coefficients, 80
- Zic2
 - retinal ganglion cell axon divergence at chiasm and, 394f, 395
 - as retinal ganglion cell marker, 193
- Zonular apparatus, 129, 130f
- ZRDCT strain, 269